Avian influenza A (H7N9) virus: from low pathogenic to highly pathogenic

William J. Liu (✉)[1,2], Haixia Xiao[3], Lianpan Dai[4], Di Liu[5,6,7,8], Jianjun Chen[5,6,7,8], Xiaopeng Qi[9], Yuhai Bi[1,4,7,8], Yi Shi[1,4,7,8], George F. Gao[2,4,9], Yingxia Liu (✉)[1]

[1]Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People's Hospital, Shenzhen 518114, China; [2]National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China; [3]Laboratory of Protein Engineering and Vaccines, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences (CAS), Tianjin 300308, China; [4]CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China; [5]CAS Key Laboratory of Special Pathogens and Biosafety, Chinese Academy of Sciences, Wuhan 430071, China; [6]National Virus Resource Center, Chinese Academy of Sciences, Wuhan 430071, China; [7]University of Chinese Academy Sciences, Beijing 100049, China; [8]Center for Influenza Research and Early Warning, Chinese Academy of Sciences, Beijing 100101, China; [9]Chinese Center for Disease Control and Prevention, Beijing 102206, China

Abstract The avian influenza A (H7N9) virus is a zoonotic virus that is closely associated with live poultry markets. It has caused infections in humans in China since 2013. Five waves of the H7N9 influenza epidemic occurred in China between March 2013 and September 2017. H7N9 with low-pathogenicity dominated in the first four waves, whereas highly pathogenic H7N9 influenza emerged in poultry and spread to humans during the fifth wave, causing wide concern. Specialists and officials from China and other countries responded quickly, controlled the epidemic well thus far, and characterized the virus by using new technologies and surveillance tools that were made possible by their preparedness efforts. Here, we review the characteristics of the H7N9 viruses that were identified while controlling the spread of the disease. It was summarized and discussed from the perspectives of molecular epidemiology, clinical features, virulence and pathogenesis, receptor binding, T-cell responses, monoclonal antibody development, vaccine development, and disease burden. These data provide tools for minimizing the future threat of H7N9 and other emerging and re-emerging viruses, such as SARS-CoV-2.

Keywords H7N9; HPAIV; epidemiology; clinical features; pathogenesis; hemagglutinin; immunity; vaccine

Introduction

For decades, avian influenza viruses (AIVs) have been recorded to cross species barriers and infect humans. Before 2013, the recognized H7 subtype avian influenza virus (AIV) to cause outbreaks in humans was the H7N7 virus, which caused 89 cases of influenza in the Netherlands in 2003 [1]. Almost 10 years later in March 2013, a novel reassortant avian influenza A (H7N9) virus first emerged in the Shanghai and Anhui Province of China [2]. Since then, this virus has spread from eastern to southern and northern China; thus far, 1568 laboratory-confirmed

cases of human infection with H7N9 viruses with a mortality rate of 39.2% have been reported to the World Health Organization (WHO) [3,4].

The emergence of H7N9 viruses seems to have opened Pandora's box. During the first four waves of the H7N9 influenza epidemic, the H7N9 viruses that circulated among poultry and occasionally caused human cases in China were classified as low-pathogenic (LP) AIVs (LPAIVs), which caused asymptomatic infections in poultry [4,5]. New isolates emerged later, possessing a cleavage site of polybasic amino acids originating from the insertion of four amino acids into the hemagglutinin (HA) protein [6,7] and exhibiting high pathogenicity to chickens during wave 5 from 2016 to 2017 [8–10]. Several outbreaks of these highly pathogenic (HP) AIVs (HPAIVs) on poultry farms have resulted in the deaths of approximately 110 000 birds across 10 provinces [11] and a series

of human cases.

A series of public health intervention strategies involving different institutes under the Task Force of Joint Prevention and Control System in China have responded well to the outbreak and controlled the epidemic [12]. Several studies have shown that the closure of live poultry markets (LPMs) in the cities that were most affected by H7N9 epidemics was highly effective in reducing the risk of H7N9 infection in humans [13–15]. Other sustainable and effective interventions in the LPM system, including rest days and the banning of live poultry overnight, also reduced the risk of this zoonotic influenza. A bivalent inactivated H5/H7 vaccine for chickens was also introduced [16]. Since wave 5, only sporadic cases of human infections have been reported. Therefore, the multiple strategies against emerging H7N9 viruses seem to have been quite successful thus far [17]. Here, we review the current characteristics of the H7N9 viruses that were identified while controlling their spread in terms of molecular epidemiology, clinical manifestations, virulence and pathogenesis, receptor binding, antibody and T cell immunity, vaccine development, and disease burden. These data extend our understanding and reduce the current and future threats posed by H7N9 and other zoonotic viruses such as SARS-CoV-2.

Molecular epidemiology and evolution

Origin and genesis of H7N9 AIVs

The genesis and origin of the H7N9 viruses were inferred at the beginning of the H7N9 epidemic on the basis of the genome sequences of the H7N9 viruses and other AIVs. Genetic analyses indicated that H7N9 is a triple reassortant of the H7, N9, and H9N2 AIVs (Fig. 1A) [3,18]. The HA of H7N9 is most closely related to that of H7N3 strains isolated from Zhejiang Province, whereas N9 neuraminidase (NA) may have originated from the H7N9 viruses identified in ducks and wild birds in Korea. Long-term surveillance data for domestic poultry suggested that the two segments were transferred from wild birds to domestic ducks along the East Asian flyway and then to chickens in LPMs (Fig. 1A) [3,19–21]. One type of enzootic H9N2 virus that has become predominant in chickens since 2010 provided all six internal genes and established the novel H7N9 virus by reassortment (Fig. 1A) [22]. Further analysis found that reassortment events likely occurred in the Yangtze River Delta around 2011–2012 [3,20]. According to an in-depth evolutionary analysis of genomic sequences, the H7N9 viruses may have been generated via at least two steps of sequential reassortment involving distinct H9N2 donor viruses in different hosts [23]. Wu *et al.* suggested that the first reassortment event likely occurred in wild birds and generated the SH/1-like viruses

(A/Shanghai/1/2013(H7N9)). In the second event, the reassortment of SH/1-like viruses and A/chicken/Jiangsu/ZJ4/2013(H9N2)-like viruses led to the emergence of the diverse genotypes of the H7N9 viruses in China. Although the genesis and origin of H7N9 have been inferred, the details of the precise events remained unclear because at that time, surveillance data for domestic/wild birds were still scant.

Evolution of H7N9 AIVs since 2013

The H7N9 viruses that circulated in domestic poultry in China have caused five epidemic waves of human infections and evolved continuously and substantially since their emergence in 2013 [3,8,20,24–26].

Across all five epidemic waves of human infections (2013–2017), the HA and NA genes of the H7N9 viruses have shown sequential evolution insofar as the surface proteins of the isolates in the later waves were derived from those in the earlier waves [19,27]. The H7N9 viruses of wave 1 were mainly from the Yangtze River Delta region and had similar surface proteins, suggesting that these viruses had a common source [20,24,25,28]. The H7N9 viruses of wave 2 were derived from those of wave 1, and the first re-emergent H7N9 virus of wave 2 was very similar to the viruses of the first wave [24,29]. In wave 2, the viruses dispersed from the Yangtze River Delta region to the Pearl River Delta region; they circulated in both regions and formed two regional lineages (Fig. 1B). The viruses of wave 3 were phylogenetic related to those in wave 2, and the majority of viruses of wave 3 were detected in the Pearl River Delta region (Fig. 1B) [24,25]. The viruses of waves 4 and 5 were mixed and clustered together, thus showing a genetically close relationship (Fig. 1B). The viruses of wave 4 mainly circulated in the Pearl River Delta region, whereas those of wave 5 circulated in the Yangtze River Delta region and the Pearl River Delta region (Fig. 1B). Phylogenetic analysis showed that the genetic diversity and population size of the H7N9 viruses increased across the five epidemic waves. In the first wave, H7N9 displayed low nucleotide diversity because it had insufficient time to accumulate mutations [30]. After the first outbreak, H7N9 experienced rapid population expansion, which was accompanied by its dissemination from the Yangtze River Delta to the Pearl River Delta region [24,30].

Historically, among all 16 subtypes of AIVs, only H5 and H7 possess HA that has acquired basic amino acids at the cleavage site. This phenomenon converted these viruses from LP to HP. Unsurprisingly, this conversion also occurred in H7N9. In the first four epidemic waves, the H7N9 AIVs were classified as LPAIVs. During December 2016 and January 2017, some H7N9 viruses with a multiple basic motif (PKRKRTA(R/G), PKGKRTA (R/G), or PKGKRIA(R/G)) at the cleavage site of the HA

Fig. 1 Origin and evolution of H7N9 viruses. (A) Schematic of the origin and dynamic reassortment of H7N9 viruses. The migratory birds, ducks, chickens, and humans involved in the emergence and outbreaks of H7N9 are shown. The dashed line arrow and circle of N9 represent the uncertain presence of N9 in ducks as indicated by a previous study [19]. Colored internal gene names in clouds represent diversified H9N2 gene pools. The specific reassortment of H7N9 with the H5N6 and H6N6 viruses is also shown. HP represents the highly pathogenic H7N9 viruses, which have also caused human infections. (B) Maximum likelihood (ML) trees of the surface genes of the H7N9 viruses in all human infections. Sequences of the surface genes of the H7N9 viruses in all human infections were downloaded from the NCBI Influenza Virus Database and Global Initiative on Sharing All Influenza Data for phylogenetic analysis. ML trees were inferred with the software RAxML under the GTRGAMMA model with 1000 bootstrap replicates by using A/Shanghai/02/2013 as the root. The background colors of the branches show the time at which the corresponding virus was isolated and are classified as waves 1 to 5 and after wave 5. Colored strips far from the tree indicate the regions from which the corresponding viruses were isolated. The Yangtze River Delta region, the Pearl River Delta region, and other regions are labeled in red, blue, and no-color, respectively. HP in the upper panel shows the cluster containing all HP H7N9 isolates.

protein were identified as HP in poultry [6,8,31]. The HA and NA genes of the HP-H7N9 viruses have common ancestors (Fig. 1B) [8].

The H7N9 viruses have not only established regionally distinct lineages but have also greatly increased in genotypic diversity through internal gene reassortment [30]. Across the five epidemic waves of H7N9 viruses, their internal genes have undergone complex reassortment with those of different AIVs, especially with those of the H9N2 viruses in poultry. In the first wave, high genetic heterogeneity was observed in internal genes, and at least 26 genotypes were identified [19,32]. A dynamic reassortment model was used to explain the evolution of the H7N9 viruses in the first wave (Fig. 1A) [19]. During the first wave, these viruses entered enzootic AIV hosts and began to recruit internal genes to adapt themselves to their new hosts [19]. An analysis of the first-wave viruses from humans and evidence from animal models revealed that continuous reassortment and amino acid substitutions, such as at residue 627 of polymerase basic 2 (PB2), mediated the adaptation of the H7N9 viruses to humans through their interspecies transmission [32,33]. During waves 2 and 3, the internal genes were further divided into various clades [25]. Genetic heterogeneity increased, leading to the creation of 93 genotypes, although most were transient [25]. This dynamic reassortment has resulted in the abundant genotypes of the H7N9 viruses. A recent study provided evidence for the reassortment of H7N9 with the H5N6 and H6N6 viruses, suggesting that the H7N9 viruses had a larger gene pool than that previously thought when they recruited these internal genes [34].

Clinical features

As infection by other severe viral pneumonias, most H7N9-infected patients develop pneumonia that does not respond to broad-spectrum antibiotics directed against typical and atypical bacteria [35]. The pneumonia typically extends to both lungs, and the patient deteriorates rapidly. Fever and coughing are the most common symptoms together with sputum production, dyspnea, and hemoptysis [36]. Patients infected with H7N9 have other nonspecific symptoms, including headaches, fatigue, and myalgia. Chest radiography or computed tomography scans usually show bilateral ground-glass opacities and consolidation, which are typical characteristics of viral pneumonia (Fig. 2). Other radiographic features include interlobular septal thickening, centrilobular nodules, reticulation, cystic changes, bronchial dilatation, subpleural linear opacities, and pleural effusion [37–39]. In moribund patients, the common outcomes are acute respiratory distress syndrome, severe pneumonia, multiple organ failure, and death at 8–43 days after symptom onset [9,36,37,40].


Fig. 2 Radiographic findings in A (H7N9) pneumonia. Chest radiograph (A) and computed tomography scan (B) showing bilateral ground-glass opacities and consolidation.

Laboratory tests showed lymphopenia and thrombocytopenia in over 88% and 73% of patients, respectively [36]. Severe H7N9 infection is associated with elevated levels of C-reactive protein, serum creatinine, and myoglobin and with T cell lymphopenia (Table 1) [41]. Many patients experience nosocomial bacteremia and bacterial pneumonia, including infections with *Acinetobacter baumannii*, *Klebsiella pneumonia*, and *Pseudomonas aeruginosa* [39,42,43]. Given that the majority of the patients have already received broad-spectrum antibiotics, most of the organisms causing these nosocomial infections are resistant to multiple antibiotics [42].

During wave 5, which started in October 2016, 766 laboratory-confirmed cases and 288 deaths (case fatality rate (CFR): ~37.6%) were recorded in China by the end of September, 2017. The HPAIV H7N9 variant that emerged in cases during wave 5 has been identified as the causative pathogen of several human infections [6,8]. Human cases of infection with HP-H7N9 AIVs were identified in Guangdong, Guangxi, Fujian, Hunan, Shaanxi, Hebei, Henan, and Yunnan provinces [6,27,44]. However, several other provinces, such as Heilongjiang, Inner Mongolia, Shandong, Beijing, and Tianjin, have also reported HP-H7N9 outbreaks in poultry or its detection in LPMs. Notably, H7N9 infections in several family clusters and in patients in the same hospital wards were also reported.

Although the greatest numbers of human cases occurred in wave 5 [7,45], current evidence indicates that the newly emergent HP-H7N9 causes a disease in humans with a severity similar to the severity of LP-H7N9. A statistical analysis of several cases in Shenzhen, China, identified no significant differences in patients infected with HP- or LP-H7N9 in terms of age, days from onset to hospital admission, coexisting chronic medical conditions, and complication incidence during hospitalization. Patients in both groups also showed similar patterns of PaO_2/FiO_2 dynamics and imaging characteristics associated with pathological changes (Table 1) [37]. The overall case fatality rate (CFR) in Shenzhen was approximately 13.3%,

Table 1 Clinical characteristics and laboratory results of subjects hospitalized for infection with low pathogenic and highly pathogenic H7N9 during the five waves of the H7N9 epidemic in China

Parameter[a]	HP (wave five, $N = 5$)[b,c]	LP (wave five, $N = 7$)	P value[e]	LP (first four waves, $n = 123$)[d]	P value[e]
WBC ($\times 10^9$/L)[f]	5.02 (4.81–5.6)	3.88 (3.52–6.39)	NA[g]	4.5 (2.9–6.2)	NA
LYM ($\times 10^9$/L)	0.505 (0.48–0.56)	0.53 (0.47–0.86)	NA	0.5 (0.3–0.7)	NA
NEU ($\times 10^9$/L)	4.18 (4.13–4.73)	3.22 (3.1–4.97)	NA	3.3 (2.2–5.4)	NA
PLT ($\times 10^9$/L)	166 (160–221.5)	157 (139–198.3)	NA	114 (82–147.5)	NA
AST (U/L)	64.2 (38.5–107.4)	88.3 (42.85–224.9)	NA	53 (38–96.5)	NA
ALT (U/L)	63.7 (40.4–112.4)	74 (44.05–119.7)	NA	35.5 (24–64.5)	NA
CRE (μmol/L)	60 (53–107.15)	89.65 (62.1–106.6)	NA	70.7 (58.3–85)	NA
CK (U/L)	182 (144–239.5)	163.8 (123.75–354)	NA	195 (96–562)	NA
CRP (nmol/L)	92.65 (74.6–176.2)	72.5 (49.7–83.3)	NA	65 (25–113)	NA
ALB (g/L)	31.9 (26.3–32.5)	32.6 (32.5–33.7)	NA	NA	NA
LDH (U/L)	711.5 (573.8–848.5)	994.5(475.8–1596.5)	NA	498 (388–661)	NA
Leukopenia	0/4 (0%)	4/7 (57%)	0.194	48/105 (46%)	0.129
Lymphopenia	4/4 (100%)	5/5 (100%)	NA	88/99 (89%)	1.000
Neutropenia	0/4 (0%)	0/6 (0%)	NA	13/103 (13%)	1.000
Neutrophilia	0/4 (0%)	0/6 (0%)	NA	5/103 (5%)	1.000
Thrombocytopenia	0/3 (0%)	3/6 (50%)	0.464	80/104 (77%)	0.015
Elevated AST	2/4 (50%)	4/7 (57%)	1.000	54/103 (52%)	1.000
Elevated ALT	2/3 (66.7%)	4/6 (66.7%)	1.000	34/100 (34%)	0.279
Elevated CRE	1/3 (33.3%)	1/6 (16.7%)	1.000	11/103 (11%)	0.305
Elevated CK	2/4 (50%)	2/6 (33.3%)	1.000	48/98 (49%)	1.000
Elevated CRP	4/4 (100%)	5/5 (100%)	NA	83/92 (90%)	1.000
Elevated LDH	4/4 (100%)	6/6 (100%)	NA	89/98 (91%)	1.000

[a]Results were obtained from patients at the earliest available time point after hospitalization. [b]Clinical data from two HP-H7N9 human cases are presented in this study. In addition, three cases from previous reports were included in this analysis. [c]Reference group. [d]Clinical data of the 123 cases from previous report were included in this analysis. [e]A P value between 0.01 and 0.05, 0.001 and 0.01, and below 0.001 was considered statistically significant, very significant, and extremely significant, respectively. [f]Values shown represent the mean and interquartile range. [g]NA: not available.

which is far lower than the nationwide CFR during the five waves of human H7N9 infections (39.6%) [7,46]. This result may be attributable to several comprehensive measures taken, including the reasonable use of NA inhibitors, mechanical ventilation, corticosteroids, antibiotics, and fluid infusion, and the strict prevention and control of nosocomial infections. However, this difference requires further confirmation because the sample sizes in the studies were limited.

Despite the absence of evidence showing that HP-H7N9 is more virulent than LP-H7N9 in humans or more transmissible as a consequence of its increased infectivity of the respiratory epithelium in the nasal passages [6,47], the pathogenesis of HP-H7N9 in poultry and its resistance to NA inhibitors (NAIs) may still affect its human infection characteristics. The case numbers showed that in the first four waves, patients infected with HP-H7N9 had a higher CFR (14/28, 50%) than those infected with LP-H7N9 (324/798, 40.6%) [37,45]. Poultry infected with HP-H7N9 become sick and may shed high concentrations of the virus, increasing the risk of human infection. The emergence of antiviral resistance is associated with adverse clinical outcomes for human H7N9 infections [47]. The overall incidence rate of NAI resistance in HP-H7N9 carrying the mutation R292K is approximately 28% (13/46), which is far higher than that in LP-H7N9 (34/1225, 2.8%) [37]. This characteristic suggests that HP-H7N9 may develop the NAI-resistance mutation easily during antiviral treatments with NAIs. This situation may be one reason for the higher CFR of HP-H7N9 [37]. Therefore, the NAI-resistance mutation should be closely monitored during the treatment of patients infected with HP-H7N9.

Virulence and pathogenesis

When H7N9 emerged in 2013 [48], the LP-H7N9-infected chickens lacked obvious clinical symptoms, and the virus mainly replicated in the upper respiratory tract [49,50]. However, LP-H7N9 caused severe disease in humans in the first four waves of the epidemic [5]. Over 85% of H7N9-infected patients had a history of exposure to poultry. An HP-H7N9 mutant in which the insertion of four amino acids generated multiple basic amino acids at the cleavage site of the HA protein emerged during epidemic wave 5 [6,7]. This mutant caused severe disease and

outbreaks in poultry [8,51]. Importantly, a study showed that one HP-H7N9 strain was more pathogenic to ferrets than LP-H7N9 with evidence of its effective transmission via respiratory droplets [52]. Another study showed that although HP-H7N9 isolates were more virulent than LP-H7N9 viruses in mouse and ferret animal models, these viruses were poorly transmissible via respiratory droplets [53]. However, the virulence and transmissibility of an HP-H7N9 strain substantially increased in mammals after adaptation during one passage in ferrets [54]. In fact, different epidemic H7N9 strains, including LP-H7N9 and HP-H7N9, displayed diverse virulence and transmissibility in mammals, and the public risk of H7N9 did not increase during wave 5 [55]. As discussed in the clinical section above, the current evidence does not support the notion that HP-H7N9 is more virulent or transmissible than LP-H7N9 in humans.

The contributions of the six internal genes of H7N9 (A/Anhui/1/2013) to its virulence in mice were evaluated on the basis of the H9N2 backbone. The PB2, matrix (M), and nucleoprotein (NP) genes were identified as the virulence genes necessary for high pathogenicity in mice. In particular, the gene segments from H9N2 that recombined with the H7N9 PB2 gene caused more severe disease in mice with higher mortality rates and cytokine secretion than the parent H7N9 (A/Anhui/1/2013) and other H9N2 recombinants that included different internal H7N9 genes [33]. The E627K mutation in PB2 was identified as the critical mutation and conferred the high virulence of H7N9

in mice (Table 2). This critical mutation emerged as early as 4 days after infection [33]. In addition to E627K, other mutations, such as T271A, Q591K, D701N, A588V, and K526R, in PB2 contribute to the pathogenicity and replication capacity of H7N9 in mammals and/or mammalian cells (Table 2) [56–58]. Notably, we observed the gradual replacement of 627E by 627K in H7N9, termed "genetic tuning" in the longitudinally collected specimens from infected patient and the correlation between rapid host adaptation of H7N9 PB2-E627K and the fatal outcome and disease severity in humans [59]. Furthermore, a long deletion (10–20 amino acid residues) in the stalk of NA increased the pathogenicity of H7N9 in mice (Table 2) [60], although no wild-type viruses with these deletions have been detected. Therefore, the mutation and evolution of H7N9 AIVs and their virulence and pathogenesis must be closely monitored. So that necessary measures can be timely implemented to control the risks posed by potential mutants.

Distinct avian-to-human receptor binding adaptation of H7

The receptor binding property of the HA protein is one of the crucial determinants of the interspecies transmission of influenza viruses. In the first step of viral entry, influenza viruses must be able to bind sialic acid (SA) receptors on the host cells to allow host jumping [61–65]. Typically,

Table 2 Critical amino acid residues in H7N9 proteins associated with viral virulence in mammals

Protein	Amino acid position	Potential biological functions
HA[a]	S138A	Responsible for the acquisition of human receptor binding capacity [70]
	T221P	
	G186V	Responsible for the acquisition of human receptor binding capacity [70,72]
	Q226L	Critical for binding the α-2,6-linked receptor and enables transmission in mammals [70,72,174,175]
	Insert-KRTA-at the HA cleavage site	Contributes to disease in mice [176]
	HA2-K64E	Reduces viral stability and replication in mice [176]
NA	19- to 20-amino-acid deletion in the NA stalk	Enhances virulence in mice [60]
PB2	T271A	Enhances viral replication in mammalian cells *in vitro* [175]
	K526R	Enhances viral replication in mammalian cells and in mice [56]
	A558V	Promotes mammalian adaptation [58]
	E627K	Associates with increased virulence of AIVs in mammals [33,175,177–179]
	Q591K	Increases pathogenicity in mice [177,178]
	D701N	
NP	V41I and/or D210E	Promotes the replication capability of H7N9 viruses at low temperature and thus might contribute to viral transmissibility [180]
	A286V	Attenuates the virulence of H7N9 viruses in mice [181]
	T437M	
NS1	V178I	Promotes viral replication in mice [182]
	P212S	

[a]H3 numbering.

AIVs preferentially bind the α-2,3-linked SA glycan receptor (avian-type receptor), whereas human influenza viruses preferentially bind α-2,6-linked SA glycan receptors (human-type receptor). Human-infecting AIVs are indicated to have originated from strains that have gradually evolved the capacity to bind human-type receptors [66].

The receptor binding site (RBS) of the HA protein consists of three critical secondary elements: the 130-loop, 190-helix, and 220-loop. The key interacting residues within each element display remarkable variations among different influenza virus subtypes; these variations result in distinct receptor binding properties [63]. The key determinant residues for human receptor binding or a human/avian receptor preference can be significantly distinct in different HA-subtype influenza viruses. A certain HA subtype can evolve from avian receptor specificity to dual-receptor tropism or even to human receptor preference via more than one pathway [67]. Through biochemical and structural studies, we have gained a substantial understanding of the determinants of the receptor binding properties of the H7 subtype influenza viruses that have caused human infections.

The H7N9 outbreak in 2013 and the more recent H7N4 human infections have highlighted the potential of the H7

subtype AIVs to adapt to human hosts and evolve into human influenza viruses [4,68,69]. Although previous studies have shown that H7N9 subtype influenza viruses have not acquired the capacity for efficient human-to-human transmission, an increase in the human-receptor binding capacity of H7 subtype AIVs was observed before and after the 2013 outbreak [70]. Based on our current knowledge, the receptor binding property of the H7 subtype HA is mainly determined by residues at two positions in RBS, i.e., residues 186 and 226 (Fig. 3) [71–73]. Two other sites, namely, residues 138 and 221, also play a cooperative role in viral binding affinity [70]. In contrast to the human-receptor binding capacity of the other HA subtypes, including the H2, H3, H4, and H5 subtypes, canonical signatures (such as the Q226L substitution) are not the key to the human-receptor binding capacity of the H7 subtype HA. Instead, a single G186V substitution determines the human-receptor binding capacity of avian H7 subtype HA and may have emerged much earlier in the evolutionary process than other substitutions [70] (Fig. 3). By contrast, the Q226L substitution may have occurred later than other substitutions to further regulate viral affinity or preference for human-type receptors. Importantly, L226 only favors human- and avian-type receptors when paired with hydrophobic


Fig. 3 Diagram of the evolutionary routes of H7N9 HA. H7 HA with different residue combinations at receptor binding sites (G186/Q226, V186/L226, G186/L226, and V186/Q226) are represented by surface sheets and colored cyan, violet, wheat, and orange. SA receptor analogs are shown as sticks and colored on the basis of elements (carbon, yellow; oxygen, red; nitrogen, blue). The positions of residues 186 and 226 are highlighted in purple.

residues at positions 138 and 186 [70]. Structural evidence indicates that the G186V substitution changes the local hydrophobicity of RBS, thus affecting the conformation of the side chain of residue E190, which directly interacts with the SA receptor [70]. However, the Q226L substitution alters the stability of the 220-loop, affecting viral binding to human- and avian-type receptors [70]. Bioinformatic analyses have shown that the circulating H7 subtype influenza viruses are mainly dual-receptor tropic with a preference for human receptors [7,70]. Artificial H7 protein mutants with human receptor specificity have also been developed in the laboratory [74]. These mutants may be used to reveal the risk of the further adaptation of the H7 subtype influenza viruses.

Cell-mediated immunity

Cell-mediated immunity in the acute phase of H7N9 infection

Infection with the H7N9 influenza virus is characterized by high inflammatory cytokine and chemokine levels in the lungs and peripheral blood; this condition is called hypercytokinemia or cytokine storm [75–77] and is thought to be correlated with severe disease in patients with H7N9. However, the hypercytokinemia levels caused by H7N9 are lower than those caused by H5N6 [76,78–82]. A comparative study showed that the concentrations of some cytokines induced by HP-H7N9 in human patients seemed higher than those induced by LP-H7N9, although the differences were not significant [37].

A dramatic increase in lymphocyte subgroups was observed in the early stage of H7N9 infection in patients who survived. This increase led to significantly elevated levels of most lymphocyte subgroups during the recovery phase. By contrast, in patients who succumbed to infection, the T cell population remained at a low level during hospitalization and decreased suddenly on the day of death [83]. In the acute phase, the expression of human leucocyte antigen (HLA)-DR on CD14$^+$ cells was negatively correlated with the severity of H7N9 infection and might result in impaired T cell response due to low antigen-presenting capacity [84]. Patients with severe H7N9 presented with a delayed T cell response in the acute phase. However, robust early CD8$^+$ T cell responses in patients were correlated with rapid recovery from the disease [85]. The early transient prevalence of highly activated CD38$^+$HLA-DR$^+$PD-1$^+$CD8$^+$ T cells was observed in surviving patients, whereas the prolonged persistence of this cell population was observed in ultimately fatal cases [85]. The differential clonal expansion kinetics of T cell receptor αβ were observed between the surviving patients infected with H7N9 and those who died [86]. Deep-sequencing the transcriptomes of T and B

cells from H7N9-infected patients showed higher B cell diversity but lower T cell diversity in surviving patients than in those who died [87]. The studies on the immune status of hospitalized patients suggested that T cells play a pivotal role in immune protection against H7N9 during the acute phase of the disease.

Cell-mediated immunity in convalescence

A series of studies on the immunology of H7N9 survivors during follow-up identified uncommon characteristics of the survivors' T cell responses after severe AIV infection. A 1-year follow-up of survivors showed that the total lymphocyte count had normalized by 1 month postinfection [88]. However, evidence for the ongoing impairment of the immune responses in patients who had suffered severe infections was found; this evidence included reduced HLA-DR expression by CD14$^+$ monocytes and reduced interferon-γ (IFN-γ) production by T cells. During nonspecific stimulation with *Streptococcus* antigens, T cell responses were abnormal in severely affected patients 1 month after infection compared with those in patients with mild symptoms. The abnormal immune status of the general T cell population returned to normal by 3 months postinfection [88]. In a cohort of H7N9 survivors who were followed up for 15 months after infection, although the H7N9-specific antibody concentrations declined over time, the frequency of virus-specific IFN-γ-secreting T cells increased within 1 year of infection [89]. This phenomenon was confirmed in another cross-sectional study involving survivors at 36 months after infection [90]. This increasing trend over time within 1 year of infection was more obvious in patients aged ≥ 60 years and in critically ill patients requiring ventilation during their infections. This trend was attributed to the initially considerably lower percentage of H7N9-specific IFN-γ-secreting T cells within 4 months of infection in these patients than in younger and more mildly affected patients. The levels of antigen-specific CD8$^+$ T cells expressing the lung homing marker CD49a in samples obtained at 6–8 months after H7N9 infection were higher than in those obtained at 1.5–4 months after infection [89]. In our study on survivors who were followed up for 36 months, the percentage of virus-specific cytokine-secreting memory CD8$^+$ T cells peaked in the survivors at 14 months after infection and declined gradually thereafter [89]. A linear regression analysis showed that underlying medical conditions, lack of antiviral therapy, and female sex were predictors of higher T cell responses in the survivors. The prolonged reconstruction and evolution of virus-specific T cell immunity in survivors of H7N9 infection showed new immune features directed against severe AIV infection, which may have implications for T cell-directed immunization strategies.

Cross-reactive T cell immunity between H7N9 and other influenza viruses

The envelope proteins of the H7N9 virus, such as HA and NA, are highly variable. By contrast, the internal proteins, such as matrix 1 (M1), NP, and polymerase basic 1 (PB1), of H7N9 share highly conserved sequences with those of other subtypes of the influenza A virus (IAV). A series of comparable studies showed that a strong cross-reactive T cell response was induced by seasonal IAVs and H7N9 [91,92] despite substitutions in the T cell epitopes. CD8[+] T cells that cross-reacted with H7N9 viruses were already present in the peripheral blood of a healthy European population before the H7N9 epidemic. In particular, the H7N9 variant of the $NP_{418-426}$ epitope was recognized by seasonal H3N2-specific CD8[+] T cells derived from an HLA-B*35 subject [91]. Quinones-Parra *et al.* also showed that antigenic peptides derived from H7N9 were recognized by memory CD8[+] T cells that were generated during previous influenza exposure but that the capacity for recognition varied among different ethnicities with different diversities of HLA alleles [93]. As indicated by our previous study, cross-reactivity between different influenza viruses may be attributable to immunodominant T cell epitopes [94]. In a recent study, we found that although 2009 pandemic H1N1 (pH1N1)-specific T cells showed biased reactivity to human-infecting H5N1, the pre-exposure of mice to H1N1 provided protection against H5N1 and H7N9 challenge [95]. This result was confirmed in other studies on mice wherein cross-reactive memory T cells offered heterosubtypic protection against H7N9 [96,97]. Therefore, the pre-existing cross-reactive T cell immunity induced by previous infection with the seasonal influenza virus in the population may contribute to the clearance of H7N9 and symptom relief in patients [4].

Although broadly cross-reactive T cell immune responses are induced by H7N9 and other seasonal influenza viruses, H7N9-virus-specific substitutions in dominant T cell epitopes can lead to immune evasion in subjects naïve to H7N9 [92,93,95]. We previously demonstrated that two amino acid substitutions in an HLA-A*1101-restricted peptide, H1-P22 ($NP_{188-198}$: TIA-MELIRMIK in pH1N1), led to dramatic antigenic variability in the corresponding T cell epitope H7-22 (TMVMELIRMIK) in H7N9 (Fig. 4A–4C) [92]. Another M1-protein-derived peptide, H1-P25 ($M1_{99-109}$: LYKKLKREITF in pH1N1), with a HLA-A*2402 restriction has a dominant mutation with a substitution at position nine from isoleucine (Ile) to methionine (Met) in peptide H7-P25 (LYKKLKREMTF) of H7N9. This substitution does not alter the binding affinity to HLA-A*2402 but alleviates T cell recognition in HLA-A*2402[+] individuals. The crystal structures of HLA-A*2402 when complexed with peptide H1-P25 or H7-P25 (Fig. 4D–4F) show that residue Ile9 of H1-P25 inserts into the E pocket

of the HLA-A*2402 groove, whereas the side chain of the mutated residue Met9 of H7-25 protrudes from the E pocket and may come into contact with TCR [95]. Similarly, the substitutions in the HLA-A*0101-restricted T cell epitope NP_{44-52} of H7N9 made the peptide–HLA complex less stable and less accessible to cytotoxic T cells compared with corresponding peptide from seasonal influenza viruses [93]. A combination of structural and functional studies have demonstrated that immunogenic variations are largely modulated by substitutions in H7N9, thus affecting HLA binding and/or TCR recognition.

Therapeutic monoclonal antibodies against H7N9 influenza virus

H7 head-reactive monoclonal antibodies

Broadly neutralizing monoclonal antibodies (bnMAbs) are becoming a promising solution to accommodate the antigenic changes and diversity in influenza viruses. Two classes of bnMAbs have been identified: one that targets the HA head and another that recognizes the HA stem region. The membrane-distal globular head of HA is highly immunogenic and is the main target of the monoclonal antibodies (MAbs) induced during viral infection or vaccination. Thus far, several H7 HA head-targeting therapeutic MAbs have been identified in H7N9-infected patients, H7N9-vaccinated individuals, and H7-HA-vaccinated mice [98–108]. Most H7 HA head-targeting MAbs recognize the RBS and its adjacent areas [100,109]. Given that these RBS-reactive MAbs mainly function as inhibitors that block viral attachment and entry, they usually have hemagglutination inhibition (HAI) activity [98–107]. Notably, some RBS-reactive MAbs mimic the interaction of the SA receptor by directly inserting one complementarity-determining region loop into the RBS [100,109]. Some HAI antibodies, such as H7.167, bind to epitopes adjacent to the RBS of H7 HA [104].

Apart from HAI MAbs, H7 HA head side-, edge-, and bottom-reactive MAbs, such as 22-3E05, 07-5B05, and m826, have also been discovered in individuals who were administered an H7N9 vaccine or in a naïve human antibody library [103,110]. Two neutralizing MAbs, 22-3E05 and 07-5B05, derived from H7N9 vaccinees lack HAI capability but can neutralize H7N9 *in vitro* [103]. Escape mutants generated from those MAbs suggest that HA1 R65 and K182 are critical residues for the binding of 07-5B05 and 22-3E05, respectively [103]. The exact epitopes and neutralization mechanisms of these two MAbs have yet to be investigated. Another MAb, m826, was screened from a very large naïve antibody library constructed from the peripheral blood mononuclear cells of healthy adult donors. Interestingly, m826 cannot neutralize

Fig. 4 Molecular basis for cross-reactive T cell immunity and immune evasion between the H7N9 and 2009 pH1N1 influenza viruses. (A, B) 2009 pH1N1-derived T cell epitope peptide H1-P22 (PDB code: 4MJ5) and substitution peptide H7-P22 from H7N9 (PDB code: 4MJ6) presented by HLA-A*1101. The peptide-binding groove is shown as the vacuum electrostatic surface potential of the HLA-A*1101 H chain. (C) Alignment of peptides H1-P22 (green) and H7-P22 (yellow). The α1-helix of the HLA-A*1101 H chain is shown as a white spiral ribbon behind the peptide. (D, E) Peptide H1-P25 in pH1N1 (PDB code: 5WWU) and its substitution peptide in H7N9 H7-P25 (PDB code: 5WXD) presented by HLA-A*2402. The peptide binding groove is shown by the vacuum electrostatic surface potential of the HLA-A*2402 H chain. (F) Alignment of peptides H1-P25 (cyan) and H7-P25 (orange). The α1-helix of the HLA-A*2402 H chain is shown as a white spiral ribbon behind the peptide. The names and positions of the conserved residues in the peptides are denoted by black letters and numbers, respectively. Conserved residues are shown with colored sticks. Residue substitutions are shown in underlined bold text in colors corresponding to the peptides. Residue substitutions are shown with colored spheres and sticks.

the virus *in vitro*; instead, it induces very strong antibody-dependent cellular cytotoxicity (ADCC) and is highly effective against H7N9 virus infection *in vivo* [110]. Structural analysis revealed that m826 binds to HA with high pH-dependent affinity via a unique epitope that is distinct from the conventional HA head antigenic site [110]. This unique epitope may be fully exposed during pH-induced conformational changes in HA.

Most H7 head-reactive MAbs exert a narrow breadth of protection against the H7 influenza viruses because of the high level of sequence variation and antigenic changes in this domain, which has evolved to evade immune recognition. Thus, most head-reactive bnMAbs target the RBS and have a restricted recognition pattern within a subtype, such as H1-specific 5J8 and CH65 and H2-specific 8M2 [111–114]. A few head-reactive bnMAbs,

such as C05, F045-92, and S139/1, show binding and neutralization activity with more than one HA subtype [115–118]. However, none of these three RBS-reactive bnMAbs binds to H7 HA. Through continuous great effort, H7/H3 head-cross-reactive MAbs W3A1 and Z1B10 have been isolated from patients who were naturally infected with H7N9 [100]. Notably, W3A1 and Z1B10 show HAI and neutralization activity against H7 and H3 IAVs. A further structural analysis should clarify the antigenic breadth and potency of these two bnMAbs. A naturally occurring human HA head-reactive bnMAb, FluA-20, which recognizes a novel epitope at the HA trimer interface, was recently reported [119]. In contrast to RBS-reactive bnMAbs, FluA-20 recognizes the HA head in nearly all subtypes of IAVs with high affinity and protects mice from infection by the H7N9 virus. The

structural characterization of FluA-20 when complexed with the H1 HA-head revealed a novel epitope at the trimer interface. This novel epitope is adjacent and lateral to, but does not overlap with, the RBS and is hidden at the HA trimer interface. This configuration indicates that FluA-20 interacts with HA in a noncanonical trimeric form, thus inhibiting the cell-to-cell spread of the virus by disrupting the integrity of the HA trimer [119].

H7 stem-reactive MAbs

The HA stem region, which contains the N- and C-terminal fragments of HA1 and the full length of HA2, is responsible for viral and cell membrane fusion. This region is most conserved among the different subtypes of IAVs. It was previously believed that only the immuno-dominant HA head induces neutralizing antibodies. However, the initial discovery of C179, a stem-reactive mouse MAb, ushered in a new era of bnMAbs [120]. Many stem-targeting bnMAbs have since been discovered, and several, including CR6261, CR8020, VIS410, MHAA4549A, and MEDI8852, have entered clinical trials [121]. Most stem-reactive MAbs inhibit viral replication by locking the HA trimer in a prefusion conformation, thus preventing pH-triggered conformational changes when the virus is taken up into endocytic compartments.

After the outbreak of the H7N9 avian influenza in 2013, several H7 stem-reactive MAbs were isolated from the recipients of the H7N9 vaccine and from H7N9-infected patients [100,103,122]. These newly isolated H7 stem-reactive MAbs usually cross-react with different subtypes of HA. For example, Z3A8 and Z3B2, which were isolated from H7N9-infected individuals, are cross-reactive with H7 and H3 HA but only show neutralizing activity against H3 IAVs [100]. AF4H1K1, which was isolated from an H7N9-infected patient, binds the HAs of group 2 IAVs and protects mice from challenge with H3 and H7N9 IAVs [122]. 41-5E04, a neutralizing MAb isolated from an H7N9 vaccinee [103], competes with CR9114, a well-known stem-reactive MAb [123]. Some H7 stem-reactive MAbs, such as one human MAb (huMAb), AF4H1K1, isolated from an H7N9-infected patient, show no neutralization activity *in vitro* but instead provide protection against influenza virus infection *in vivo* [105,122]. Similar results have also been found for cross-reactive MAbs, such as 41-5D06, 07-5E01, and 24-4C01, that were isolated from H7N9-vaccinated individuals [103]. These cross-reactive non-neutralizing H7-targeting MAbs may mediate the protection afforded *in vivo* by ADCC or complement-dependent cytotoxicity through Fc–Fc receptor and Fc–complement interactions.

H7N9 NA-targeting MAbs

NA is a subdominant target of the protective immune response, and antibodies targeting NA potentially impair viral replication by inhibiting NA activity, thereby restricting viral budding and spread [124].

The first reported MAb directed against the NA of H7N9 that exerted a therapeutic effect was 3c10-3, which was generated with hybridoma technology from a mouse vaccinated with a purified inactivated H7N9/PR8 reassortant virus [125]. Epitope mapping showed that 3c10-3 binds near the NA enzyme active site, and functional studies demonstrated that 3c10-3 inhibits the enzyme activity of H7N9 NA, blocking the cell-to-cell spread of H7N9 in cell culture. 3c10-3 has similar binding affinity for wild-type H7N9 NA and a variant NA carrying the R289K mutation, which renders it resistant to the NA inhibitor oseltamivir [126]. A panel of murine N9-specific MAbs was subsequently produced from mice vaccinated with the H7N9 NA protein [127]. Some of these murine N9-reactive MAbs, including 2F6 and 10F4, are effective against oseltamivir-resistant clinical H7N9 isolates [127].

Several H7N9 N9-specific huMAbs that were isolated from two survivors of natural H7N9 infections and two H7N9 vaccinees who were administered a monovalent inactivated H7N9 vaccine formulated with adjuvant were described at the end of 2019 [128]. These huMAbs, which exhibit NA-inhibiting activity, including NA-22, NA-45, NA-73, and NA-80, bind several antigenic sites on the N9 surface of H7N9 and mainly function by blocking the egress of nascent virions from infected cells. These huMAbs provided prophylactic and therapeutic protection to H7N9-virus-infected mice, and this protection was mediated by direct virus neutralization or an Fc-region-mediated effector function [128]. Another team also reported an H7N9 N9-specific MAb, W1C7, and three broadly N1- and N9-cross-reactive NA-directed MAbs (Z1A11, Z2B3, and Z2C2) in H7N9-infected patients [129]. Among these MAbs, Z2B3 has strong NA-inhibitory activity against clade 6B.1 pH1N1 viruses [129,130]. The isolation of these N9-targeting huMAbs indicates that either H7N9 infection or immunization with a monovalent inactivated H7N9 vaccine formulated with an adjuvant can induce potent N9-specfic NA-inhibiting and protective MAbs in humans. Recently, exciting new broadly cross-reactive and protective NA-reactive huMAbs, which can bind N2 and N7 NAs, have been identified in H3N2-infected and H7N9-infected individuals but not in individuals who were administered seasonal influenza vaccines [129,131]. The current seasonal influenza vaccines rarely induce NA-reactive B cells because key NA epitopes are poorly displayed [131].

H7- and N9-reactive MAbs that are differentially cross-reactive with HA or NA subtypes compellingly suggest that influenza vaccines should be designed to optimize the immune response to HA and NA to confer broad protection against divergent IAVs.

Development of H7N9 influenza vaccines

Vaccination is the main intervention used to counter the infection of humans by influenza viruses. The first step in the development of an H7N9 influenza vaccine is the selection of candidate vaccine viruses (CVVs) for pandemic preparedness under coordination by the WHO. Identifying these CVVs allows timely vaccine production. During the first outbreak of the H7N9 epidemic, the A/Anhui/1/2013-like virus was recommended as the CVV by the WHO in May 2013. However, during wave 5 of the H7N9 epidemic in 2016, the circulating virus reacted poorly to ferret antiserum primed with A/Anhui/1/2013 CVVs. Therefore, the WHO suggested another H7N9 strain (A/Hunan/2650/2016) that had emerged in 2016 as the CVV [132]. These two viruses are LPAIVs. An A/Guangdong/17SF003/2016-like virus was also proposed by the WHO as the CVV for HPAIVs to replace the 2013 CVV [132]. A number of H7N9 influenza vaccines have now been developed on the basis of multiple platforms, and some vaccines have advanced to clinical trials in humans (Table 3).

Inactivated influenza vaccines

Inactivated influenza vaccines (IIVs) are produced via traditional approaches. These vaccines are generated by infectious influenza virus grown in eggs or cell cultures and then subjected to inactivation (whole-virus vaccines) or virion disruption with detergents (split vaccines) [133]. Whole-virus vaccines based on the A/Anhui/1/2013 virus, derived from Vero cell cultures or eggs, have been described. These vaccines were protective against H7N9 challenge in a mouse model without adjuvant [133–135]. Most whole-virus and split-virion IIVs have been produced from reassortant viruses to increase vaccine yield. In these viruses, the HA and NA genes are derived from the suggested CVV, whereas the remaining six genes are derived from the highly egg-adapted strain A/PR/8/34 [133,136]. The PR8 backbone can enhance the growth titer of the CVV and reduce its pathogenicity. A number of whole-virus vaccines have been tested in mice, ferrets, and nonhuman primates and been shown to provide effective protection against lethal H7N9 challenge [137–139]. Split vaccines are usually less immunogenic in ferrets than whole-virus preparations, and high vaccine doses and oil-in-water adjuvants are required [133].

Live attenuated influenza vaccines

Live attenuated influenza vaccines (LAIVs) are believed to be more immunogenic than IIVs because of their limited viral replication to better stimulate the immune system [140,141]. LAIVs are also reported to generate virus-specific cytotoxic CD8+ T lymphocytes, which confer heterosubtypic protection [142–146]. Two LAIV platforms based on the A/Leningrad/134/17/57 (H2N2) (Len17) and A/Ann Arbor/6/60 (AA) cold-adapted master donor viruses have been licensed for human use [147,148]. The AA-based LAIV was generated with reverse genetics by using HA and NA derived from the circulating influenza virus [148–150]. The Len17-based H7N9 LAIV was generated with classical reassortment techniques [133,151]. This LAIV is highly immunogenic and protects animal models against homologous and heterologous viral challenges [133].

Virus-like particles

Virus-like particles (VLPs) are another H7N9 vaccine platform that has advanced to clinical trials in humans. VLPs are formed via a self-assembly process that incorporates viral structural proteins (HA, NA, M1, and sometimes also M2) into ~120 nm pleomorphic particles [133]. Given that they lack viral RNA, VLPs are noninfectious and therefore safer than LAIVs. The first H7N9 VLP candidate vaccine was constructed from the full-length unmodified HA and NA genes of CVV strain A/Anhui/1/2013 and the M1 gene from A/Indonesia/05/2005 (H5N1) [152]. The H7N9 VLP was produced in insect cells with a recombinant baculovirus system. A saponin-based adjuvant (ISCOMATRIX®) or the adjuvant Matrix-M1™ was used to promote the immunogenicity and protective efficacy of the vaccine [152,153]. H7N9 VLPs have also been produced through the *Agrobacterium* infiltration-based transient expression of H7 HA protein in plants. When adjuvanted, the plant-made H7 VLP vaccine induced a protective humoral immune response in mice and ferrets [154]. In summary, H7N9 VLP vaccines are highly immunogenic, safe, and dose-sparing.

Disease burden of H7N9 infections

Human AIV infections cause considerable population morbidity with consequent healthcare and economic burdens in addition to the considerable burden of morbidity and mortality exerted by annual global epidemics of the seasonal influenza virus [155]. Studies on these disease burdens should provide evidence that can be used to plan epidemic interventions, including vaccination programs. Public-health decision-makers also require information to compare interventions such that efforts can be concentrated on interventions that are most likely to reduce morbidity and mortality [156].

During the first outbreak of H7N9 in eastern China in 2013, the disease burden was calculated on the basis of the main drivers of economic losses, especially poultry industry losses, and the burden attributable to H7N9 infection, including direct medical costs and indirect death

Table 3 H7N9 influenza vaccines in clinical development

Vaccine types	Vaccine manufacturer	Clinical trial registration
Inactivated influenza vaccines		
Subunit	Novartis, Italy	NCT01928472
Split virion	Sanofi Pasteur	NCT01938742
Split virion	Sanofi Pasteur	NCT01942265
Split virion	Sanofi Pasteur	NCT02213354
Split virion	Sanofi Pasteur	NCT02921997
Split virion	GSK	NCT02177734
Split virion	GSK	NCT01999842
Whole virus	Medigen Vacc Corp	NCT02436928
Live attenuated influenza vaccines		
LAIV (Len17-based)[a]	Microgen	NCT02480101
Prime/boost strategies		
LAIV (AA-based)/IIV (split virion)[b]	MedImmune	NCT01995695
		NCT02274545
		NCT02151344
LAIV (AA-based)/IIV (not specified)	MedImmune	NCT02957656
IIV(split virion)/LAIV (AA-based)	MedImmune	NCT02251288
Virus-like particle (VLP)		
VLP	Novavax	NCT01897701
VLP	Novavax	NCT02078674

[a]Len17: A/Leningrad/134/17/57 (H2N2). [b]AA: A/Ann Arbor/6/60 (H2N2).

and disability costs. This calculation showed that huge losses in the poultry industry followed the closing of LPMs and poultry slaughter and reached US$ 1.24 billion in the 10 affected provinces and US$ 0.59 billion in eight adjacent unaffected provinces [157]. The direct medical costs per patient with H7N9 were highly relative to the local average income [157,158]. H7N9 has the potential for further mammalian adaptation with limited human-to-human transmission [159,160]. Therefore, estimating the impact of a worldwide H7N9 pandemic remains necessary. Recently, an agent-based simulation model of an H7N9 pandemic that incorporates demographic information, human behavior, epidemiological characteristics, and nonpharmaceutical interventions was used to simulate events that might occur in the USA [161]. The results of this model reflect the worst-case scenario if an outbreak extends.

Perspectives

Only four sporadic cases of human H7N9 infections, including one case of H7N9 HPAIV in late March 2019, have been reported since October 2017 [162–165]. The epidemic of this devastating AIV appears to have gradually disappeared after five waves. On the basis of their experience in fighting against different emerging and re-emerging viruses, scientists in China and other countries have investigated this virus comprehensively

[166]. However, many scientific questions remain to be answered. (1) Although the phylogenetic analysis of the origin of H7N9 has clearly shown that a new reassortment event occurred, when, where, and how this reassortment occurred remain unclear. (2) Although a series of bnMAbs directed against H7N9 HA or NA have been identified, whether these bnMAbs will play a role in the treatment of severe infections requires further research and clinical trials. (3) The development of a human H7N9 vaccine seems more difficult than that of a chicken vaccine. A universal vaccine based on cell-mediated immunity or other potential strategies is a tantalizing goal to protect against H7N9 and other subtypes of AIVs. (4) Whether this AIV will flare up or re-emerge in some other status is a question that is especially important under the pressure of the widespread use of the H7N9 vaccine among chickens in China. The existence of H7N9 AIVs in LPMs is still continuously reported [164,167,168]. The phylogenetically adjacent H7 viruses are not only persistently detected in wild bird surveillance programs [69,169], but have already spilled over to induce human infections [170]. All these data demonstrate the continuous threat that H7N9 viruses pose to public health [25,82,171] and even global biosecurity [172,173]. Strengthening our continued vigilance and preparedness for a potential flare-up of this virus is imperative and will provide a preeminent model for the prevention and control of pandemic-related infectious diseases such as COVID-19.

Acknowledgements

Compliance with ethical guidelines

William J. Liu, Haixia Xiao, Lianpan Dai, Di Liu, Jianjun Chen, Xiaopeng Qi, Yuhai Bi, Yi Shi, George F. Gao, and Yingxia Liu declare that they have no conflict of interest. This manuscript is a review article and does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee.

References

1. Koopmans M, Wilbrink B, Conyn M, Natrop G, van der Nat H, Vennema H, Meijer A, van Steenbergen J, Fouchier R, Osterhaus A, Bosman A. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 2004; 363(9409): 587–593

2. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, Xu X, Lu H, Zhu W, Gao Z, Xiang N, Shen Y, He Z, Gu Y, Zhang Z, Yang Y, Zhao X, Zhou L, Li X, Zou S, Zhang Y, Li X, Yang L, Guo J, Dong J, Li Q, Dong L, Zhu Y, Bai T, Wang S, Hao P, Yang W, Zhang Y, Han J, Yu H, Li D, Gao GF, Wu G, Wang Y, Yuan Z, Shu Y. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013; 368(20): 1888–1897

3. Liu D, Shi W, Shi Y, Wang D, Xiao H, Li W, Bi Y, Wu Y, Li X, Yan J, Liu W, Zhao G, Yang W, Wang Y, Ma J, Shu Y, Lei F, Gao GF. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses. Lancet 2013; 381(9881): 1926–1932

4. Liu J, Xiao H, Wu Y, Liu D, Qi X, Shi Y, Gao GF. H7N9: a low pathogenic avian influenza A virus infecting humans. Curr Opin Virol 2014; 5: 91–97

5. Kile JC, Ren R, Liu L, Greene CM, Roguski K, Iuliano AD, Jang Y, Jones J, Thor S, Song Y, Zhou S, Trock SC, Dugan V, Wentworth DE, Levine MZ, Uyeki TM, Katz JM, Jernigan DB, Olsen SJ, Fry AM, Azziz-Baumgartner E, Davis CT. Update: increase in human infections with novel Asian lineage avian influenza A (H7N9) viruses during the fifth epidemic — China, October 1, 2016 – August 7, 2017. MMWR Morb Mortal Wkly Rep 2017; 66(35): 928–932

6. Zhang F, Bi Y, Wang J, Wong G, Shi W, Hu F, Yang Y, Yang L, Deng X, Jiang S, He X, Liu Y, Yin C, Zhong N, Gao GF. Human infections with recently-emerging highly pathogenic H7N9 avian influenza virus in China. J Infect 2017; 75(1): 71–75

7. Quan C, Shi W, Yang Y, Yang Y, Liu X, Xu W, Li H, Li J, Wang Q, Tong Z, Wong G, Zhang C, Ma S, Ma Z, Fu G, Zhang Z, Huang Y, Song H, Yang L, Liu WJ, Liu Y, Liu W, Gao GF, Bi Y. New threats from H7N9 influenza virus: spread and evolution of high- and low-pathogenicity variants with high genomic diversity in wave five. J Virol 2018; 92(11): e00301-18

8. Qi W, Jia W, Liu D, Li J, Bi Y, Xie S, Li B, Hu T, Du Y, Xing L, Zhang J, Zhang F, Wei X, Eden JS, Li H, Tian H, Li W, Su G, Lao G, Xu C, Xu B, Liu W, Zhang G, Ren T, Holmes EC, Cui J, Shi W, Gao GF, Liao M. Emergence and adaptation of a novel highly pathogenic H7N9 influenza virus in birds and humans from a 2013 human-infecting low-pathogenic ancestor. J Virol 2018; 92(2): e00921-17

9. Wang X, Jiang H, Wu P, Uyeki TM, Feng L, Lai S, Wang L, Huo X, Xu K, Chen E, Wang X, He J, Kang M, Zhang R, Zhang J, Wu J, Hu S, Zhang H, Liu X, Fu W, Ou J, Wu S, Qin Y, Zhang Z, Shi Y, Zhang J, Artois J, Fang VJ, Zhu H, Guan Y, Gilbert M, Horby PW, Leung GM, Gao GF, Cowling BJ, Yu H. Epidemiology of avian influenza A H7N9 virus in human beings across five epidemics in mainland of China, 2013–17: an epidemiological study of laboratory-confirmed case series. Lancet Infect Dis 2017; 17(8): 822–832

10. Kang M, Lau EHY, Guan W, Yang Y, Song T, Cowling BJ, Wu J, Peiris M, He J, Mok CKP. Epidemiology of human infections with highly pathogenic avian influenza A (H7N9) virus in Guangdong, 2016 to 2017. Euro Surveill 2017; 22(27): 30568

11. Li H, Cao B. Pandemic and avian influenza A viruses in humans: epidemiology, virology, clinical characteristics, and treatment strategy. Clin Chest Med 2017; 38(1): 59–70

12. Han M, Gu J, Gao GF, Liu WJ. China in action: national strategies to combat against emerging infectious diseases. Sci China Life Sci 2017; 60(12): 1383–1385

13. Wu P, Jiang H, Wu JT, Chen E, He J, Zhou H, Wei L, Yang J, Yang B, Qin Y, Fang VJ, Li M, Tsang TK, Zheng J, Lau EH, Cao Y, Chai C, Zhong H, Li Z, Leung GM, Feng L, Gao GF, Cowling BJ, Yu H. Poultry market closures and human infection with influenza A (H7N9) virus, China, 2013–14. Emerg Infect Dis 2014; 20(11): 1891–1894

14. Yu H, Wu JT, Cowling BJ, Liao Q, Fang VJ, Zhou S, Wu P, Zhou H, Lau EH, Guo D, Ni MY, Peng Z, Feng L, Jiang H, Luo H, Li Q, Feng Z, Wang Y, Yang W, Leung GM. Effect of closure of live poultry markets on poultry-to-person transmission of avian influenza A H7N9 virus: an ecological study. Lancet 2014; 383 (9916): 541–548

15. Gao GF. Influenza and the live poultry trade. Science 2014; 344 (6181): 235

16. Zeng X, Tian G, Shi J, Deng G, Li C, Chen H. Vaccination of poultry successfully eliminated human infection with H7N9 virus in China. Sci China Life Sci 2018; 61(12): 1465–1473

17. Liu WJ, Liu D. The triphibious warfare against viruses. Sci China Life Sci 2017; 60(12): 1295–1298

18. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, Xu X, Lu H, Zhu W, Gao Z, Xiang N, Shen Y, He Z, Gu Y, Zhang Z, Yang Y, Zhao X, Zhou L, Li X, Zou S, Zhang Y, Li X, Yang L, Guo J, Dong J, Li Q, Dong L, Zhu Y, Bai T, Wang S, Hao P, Yang W, Zhang Y, Han J, Yu H, Li D, Gao GF, Wu G, Wang Y, Yuan Z, Shu Y. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013; 368(20): 1888–1897

19. Cui L, Liu D, Shi W, Pan J, Qi X, Li X, Guo X, Zhou M, Li W, Li J, Haywood J, Xiao H, Yu X, Pu X, Wu Y, Yu H, Zhao K, Zhu Y, Wu B, Jin T, Shi Z, Tang F, Zhu F, Sun Q, Wu L, Yang R, Yan J, Lei F, Zhu B, Liu W, Ma J, Wang H, Gao GF. Dynamic reassortments and genetic heterogeneity of the human-infecting influenza A (H7N9) virus. Nat Commun 2014; 5(1): 3142

20. Lam TT, Wang J, Shen Y, Zhou B, Duan L, Cheung CL, Ma C, Lycett SJ, Leung CY, Chen X, Li L, Hong W, Chai Y, Zhou L, Liang H, Ou Z, Liu Y, Farooqui A, Kelvin DJ, Poon LL, Smith DK, Pybus OG, Leung GM, Shu Y, Webster RG, Webby RJ, Peiris JS, Rambaut A, Zhu H, Guan Y. The genesis and source of the H7N9 influenza viruses causing human infections in China. Nature 2013; 502(7470): 241–244

21. Wu A, Su C, Wang D, Peng Y, Liu M, Hua S, Li T, Gao GF, Tang H, Chen J, Liu X, Shu Y, Peng D, Jiang T. Sequential reassortments underlie diverse influenza H7N9 genotypes in China. Cell Host Microbe 2013; 14(4): 446–452

22. Pu J, Wang S, Yin Y, Zhang G, Carter RA, Wang J, Xu G, Sun H, Wang M, Wen C, Wei Y, Wang D, Zhu B, Lemmon G, Jiao Y, Duan S, Wang Q, Du Q, Sun M, Bao J, Sun Y, Zhao J, Zhang H, Wu G, Liu J, Webster RG. Evolution of the H9N2 influenza genotype that facilitated the genesis of the novel H7N9 virus. Proc Natl Acad Sci USA 2015; 112(2): 548–553

23. Li G, Fox J 3rd, Liu Z, Liu J, Gao GF, Jin Y, Gao H, Wu M. Lyn mitigates mouse airway remodeling by downregulating the TGF-β3 isoform in house dust mite models. J Immunol 2013; 191(11): 5359–5370

24. Lam TT, Zhou B, Wang J, Chai Y, Shen Y, Chen X, Ma C, Hong W, Chen Y, Zhang Y, Duan L, Chen P, Jiang J, Zhang Y, Li L, Poon LL, Webby RJ, Smith DK, Leung GM, Peiris JS, Holmes EC, Guan Y, Zhu H. Dissemination, divergence and establishment of H7N9 influenza viruses in China. Nature 2015; 522(7554): 102–105

25. Bi Y, Chen Q, Wang Q, Chen J, Jin T, Wong G, Quan C, Liu J, Wu J, Yin R, Zhao L, Li M, Ding Z, Zou R, Xu W, Li H, Wang H, Tian K, Fu G, Huang Y, Shestopalov A, Li S, Xu B, Yu H, Luo T, Lu L, Xu X, Luo Y, Liu Y, Shi W, Liu D, Gao GF. Genesis, evolution and prevalence of H5N6 avian influenza viruses in China. Cell Host Microbe 2016; 20(6): 810–821

26. Zhou L, Ren R, Yang L, Bao C, Wu J, Wang D, Li C, Xiang N, Wang Y, Li D, Sui H, Shu Y, Feng Z, Li Q, Ni D. Sudden increase in human infection with avian influenza A (H7N9) virus in China, September–December 2016. Western Pac Surveill Response J 2017; 8(1): 6–14

27. Su S, Gu M, Liu D, Cui J, Gao GF, Zhou J, Liu X. Epidemiology, evolution, and pathogenesis of H7N9 influenza viruses in five epidemic waves since 2013 in China. Trends Microbiol 2017; 25 (9): 713–728

28. Zhu H, Lam TT, Smith DK, Guan Y. Emergence and development of H7N9 influenza viruses in China. Curr Opin Virol 2016; 16: 106–113

29. Chen E, Chen Y, Fu L, Chen Z, Gong Z, Mao H, Wang D, Ni MY, Wu P, Yu Z, He T, Li Z, Gao J, Liu S, Shu Y, Cowling BJ, Xia S, Yu H. Human infection with avian influenza A (H7N9) virus re-emerges in China in winter 2013. Euro Surveill 2013; 18(43): 20616

30. Xiang D, Pu Z, Luo T, Guo F, Li X, Shen X, Irwin DM, Murphy RW, Liao M, Shen Y. Evolutionary dynamics of avian influenza A H7N9 virus across five waves in mainland China, 2013–2017. J Infect 2018; 77(3): 205–211

31. Zhou L, Tan Y, Kang M, Liu F, Ren R, Wang Y, Chen T, Yang Y, Li C, Wu J, Zhang H, Li D, Greene CM, Zhou S, Iuliano AD, Havers F, Ni D, Wang D, Feng Z, Uyeki TM, Li Q. Preliminary epidemiology of human infections with highly pathogenic avian influenza A (H7N9) virus, China, 2017. Emerg Infect Dis 2017; 23 (8): 1355–1359

32. Wang D, Yang L, Gao R, Zhang X, Tan Y, Wu A, Zhu W, Zhou J, Zou S, Li X, Sun Y, Zhang Y, Liu Y, Liu T, Xiong Y, Xu J, Chen L, Weng Y, Qi X, Guo J, Li X, Dong J, Huang W, Zhang Y, Dong L, Zhao X, Liu L, Lu J, Lan Y, Wei H, Xin L, Chen Y, Xu C, Chen T, Zhu Y, Jiang T, Feng Z, Yang W, Wang Y, Zhu H, Guan Y, Gao GF, Li D, Han J, Wang S, Wu G, Shu Y. Genetic tuning of the novel avian influenza A (H7N9) virus during interspecies transmission, China, 2013. Euro Surveill 2014; 19(25): 20836

33. Bi Y, Xie Q, Zhang S, Li Y, Xiao H, Jin T, Zheng W, Li J, Jia X, Sun L, Liu J, Qin C, Gao GF, Liu W. Assessment of the internal genes of influenza A (H7N9) virus contributing to high pathogenicity in mice. J Virol 2015; 89(1): 2–13

34. Jin Y, Ren H, Teng Y, Hu M, Peng X, Yue J, Liang L. Novel reassortment of avian influenza A (H7N9) virus with subtype H6N6 and H5N6 viruses circulating in Guangdong Province, China. J Infect 2017; 75(2): 179–182

35. To KK, Ng KH, Que TL, Chan JM, Tsang KY, Tsang AK, Chen H, Yuen KY. Avian influenza A H5N1 virus: a continuous threat to humans. Emerg Microbes Infect 2012; 1(9): e25

36. Gao HN, Lu HZ, Cao B, Du B, Shang H, Gan JH, Lu SH, Yang YD, Fang Q, Shen YZ, Xi XM, Gu Q, Zhou XM, Qu HP, Yan Z, Li

FM, Zhao W, Gao ZC, Wang GF, Ruan LX, Wang WH, Ye J, Cao HF, Li XW, Zhang WH, Fang XC, He J, Liang WF, Xie J, Zeng M, Wu XZ, Li J, Xia Q, Jin ZC, Chen Q, Tang C, Zhang ZY, Hou BM, Feng ZX, Sheng JF, Zhong NS, Li LJ. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013; 368(24): 2277–2285

37. Yang Y, Wong G, Yang L, Tan S, Li J, Bai B, Xu Z, Li H, Xu W, Zhao X, Quan C, Zheng H, Liu WJ, Liu W, Liu L, Liu Y, Bi Y, Gao GF. Comparison between human infections caused by highly and low pathogenic H7N9 avian influenza viruses in Wave Five: clinical and virological findings. J Infect 2019; 78(3): 241–248

38. Wang Q, Zhang Z, Shi Y, Jiang Y. Emerging H7N9 influenza A (novel reassortant avian-origin) pneumonia: radiologic findings. Radiology 2013; 268(3): 882–889

39. Shi J, Xie J, He Z, Hu Y, He Y, Huang Q, Leng B, He W, Sheng Y, Li F, Song Y, Bai C, Gu Y, Jie Z. A detailed epidemiological and clinical description of 6 human cases of avian-origin influenza A (H7N9) virus infection in Shanghai. PLoS One 2013; 8(10): e77651

40. Li Q, Zhou L, Zhou M, Chen Z, Li F, Wu H, Xiang N, Chen E, Tang F, Wang D, Meng L, Hong Z, Tu W, Cao Y, Li L, Ding F, Liu B, Wang M, Xie R, Gao R, Li X, Bai T, Zou S, He J, Hu J, Xu Y, Chai C, Wang S, Gao Y, Jin L, Zhang Y, Luo H, Yu H, He J, Li Q, Wang X, Gao L, Pang X, Liu G, Yan Y, Yuan H, Shu Y, Yang W, Wang Y, Wu F, Uyeki TM, Feng Z. Epidemiology of human infections with avian influenza A (H7N9) virus in China. N Engl J Med 2014; 370(6): 520–532

41. Xu L, Bao L, Deng W, Dong L, Zhu H, Chen T, Lv Q, Li F, Yuan J, Xiang Z, Gao K, Xu Y, Huang L, Li Y, Liu J, Yao Y, Yu P, Li X, Huang W, Zhao X, Lan Y, Guo J, Yong W, Wei Q, Chen H, Zhang L, Qin C. Novel avian-origin human influenza A (H7N9) can be transmitted between ferrets via respiratory droplets. J Infect Dis 2014; 209(4): 551–556

42. Liu WJ, Zou R, Hu Y, Zhao M, Quan C, Tan S, Luo K, Yuan J, Zheng H, Liu J, Liu M, Bi Y, Yan J, Zhu B, Wang D, Wu G, Liu L, Yuen KY, Gao GF, Liu Y. Clinical, immunological and bacteriological characteristics of H7N9 patients nosocomially co-infected by *Acinetobacter baumannii*: a case control study. BMC Infect Dis 2018; 18(1): 664

43. Yu L, Wang Z, Chen Y, Ding W, Jia H, Chan JF, To KK, Chen H, Yang Y, Liang W, Zheng S, Yao H, Yang S, Cao H, Dai X, Zhao H, Li J, Bao Q, Chen P, Hou X, Li L, Yuen KY. Clinical, virological, and histopathological manifestations of fatal human infections by avian influenza A (H7N9) virus. Clin Infect Dis 2013; 57(10): 1449–1457

44. Yang L, Zhu W, Li X, Chen M, Wu J, Yu P, Qi S, Huang Y, Shi W, Dong J, Zhao X, Huang W, Li Z, Zeng X, Bo H, Chen T, Chen W, Liu J, Zhang Y, Liang Z, Shi W, Shu Y, Wang D. Genesis and spread of newly emerged highly pathogenic H7N9 avian viruses in mainland of China. J Virol 2017; 91(23): e01277-17

45. WHO. Monthly Risk Assessment Summary. https://www.who.int/influenza/human_animal_interface/HAI_Risk_Assessment/en/2019. Updated October 23, 2020 (accessed November 15, 2020)

46. Yang Y, Shen C, Li J, Zou R, Wong G, Peng L, Yang L, Fang S, Li J, Li X, Wu W, Jiang X, Zeng L, Lan J, Bi Y, Gao GF, Yuan J, Liu Y. Clinical and virological characteristics of human infections with H7N9 avian influenza virus in Shenzhen, China, 2013–2017. J Infect 2019; 79(4): 389–399

47. Hu Y, Lu S, Song Z, Wang W, Hao P, Li J, Zhang X, Yen HL, Shi B, Li T, Guan W, Xu L, Liu Y, Wang S, Zhang X, Tian D, Zhu Z, He J, Huang K, Chen H, Zheng L, Li X, Ping J, Kang B, Xi X, Zha L, Li Y, Zhang Z, Peiris M, Yuan Z. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013; 381(9885): 2273–2279

48. Dai J, Zhou X, Dong D, Liu Y, Gu Q, Zhu B, Wu C, Cai H. Human infection with a novel avian-origin influenza A (H7N9) virus: serial chest radiographic and CT findings. Chin Med J (Engl) 2014; 127 (12): 2206–2211

49. Watanabe T, Kiso M, Fukuyama S, Nakajima N, Imai M, Yamada S, Murakami S, Yamayoshi S, Iwatsuki-Horimoto K, Sakoda Y, Takashita E, McBride R, Noda T, Hatta M, Imai H, Zhao D, Kishida N, Shirakura M, de Vries RP, Shichinohe S, Okamatsu M, Tamura T, Tomita Y, Fujimoto N, Goto K, Katsura H, Kawakami E, Ishikawa I, Watanabe S, Ito M, Sakai-Tagawa Y, Sugita Y, Uraki R, Yamaji R, Eisfeld AJ, Zhong G, Fan S, Ping J, Maher EA, Hanson A, Uchida Y, Saito T, Ozawa M, Neumann G, Kida H, Odagiri T, Paulson JC, Hasegawa H, Tashiro M, Kawaoka Y. Characterization of H7N9 influenza A viruses isolated from humans. Nature 2013; 501(7468): 551–555

50. Zhang Q, Shi J, Deng G, Guo J, Zeng X, He X, Kong H, Gu C, Li X, Liu J, Wang G, Chen Y, Liu L, Liang L, Li Y, Fan J, Wang J, Li W, Guan L, Li Q, Yang H, Chen P, Jiang L, Guan Y, Xin X, Jiang Y, Tian G, Wang X, Qiao C, Li C, Bu Z, Chen H. H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science 2013; 341(6144): 410–414

51. OIE. Update on avian influenza in animals (types H5 and H7). https://www.oie.int/en/animal-health-in-the-world/update-on-avian-influenza. Updated October 22, 2020 (accessed November 15, 2020)

52. Imai M, Watanabe T, Kiso M, Nakajima N, Yamayoshi S, Iwatsuki-Horimoto K, Hatta M, Yamada S, Ito M, Sakai-Tagawa Y, Shirakura M, Takashita E, Fujisaki S, McBride R, Thompson AJ, Takahashi K, Maemura T, Mitake H, Chiba S, Zhong G, Fan S, Oishi K, Yasuhara A, Takada K, Nakao T, Fukuyama S, Yamashita M, Lopes TJS, Neumann G, Odagiri T, Watanabe S, Shu Y, Paulson JC, Hasegawa H, Kawaoka Y. A highly pathogenic avian H7N9 influenza virus isolated from a human is lethal in some ferrets infected via respiratory droplets. Cell Host Microbe 2017; 22(5): 615–626.e8

53. Sun X, Belser JA, Pappas C, Pulit-Penaloza JA, Brock N, Zeng H, Creager HM, Le S, Wilson M, Lewis A, Stark TJ, Shieh WJ, Barnes J, Tumpey TM, Maines TR. Risk assessment of fifth-wave H7N9 influenza A viruses in mammalian models. J Virol 2018; 93 (1): e01740-18

54. Shi J, Deng G, Kong H, Gu C, Ma S, Yin X, Zeng X, Cui P, Chen Y, Yang H, Wan X, Wang X, Liu L, Chen P, Jiang Y, Liu J, Guan Y, Suzuki Y, Li M, Qu Z, Guan L, Zang J, Gu W, Han S, Song Y, Hu Y, Wang Z, Gu L, Yang W, Liang L, Bao H, Tian G, Li Y, Qiao C, Jiang L, Li C, Bu Z, Chen H. H7N9 virulent mutants detected in chickens in China pose an increased threat to humans. Cell Res 2017; 27(12): 1409–1421

55. Bao L, Bi Y, Wong G, Qi W, Li F, Lv Q, Wang L, Liu F, Yang Y, Zhang C, Liu WJ, Quan C, Jia W, Liu Y, Liu W, Liao M, Gao GF, Qin C. Diverse biological characteristics and varied virulence of H7N9 from wave 5. Emerg Microbes Infect 2019; 8(1): 94–102

56. Song W, Wang P, Mok BW, Lau SY, Huang X, Wu WL, Zheng M, Wen X, Yang S, Chen Y, Li L, Yuen KY, Chen H. The K526R substitution in viral protein PB2 enhances the effects of E627K on influenza virus replication. Nat Commun 2014; 5(1): 5509

57. Mok CK, Lee HH, Lestra M, Nicholls JM, Chan MC, Sia SF, Zhu H, Poon LL, Guan Y, Peiris JS. Amino acid substitutions in polymerase basic protein 2 gene contribute to the pathogenicity of the novel A/H7N9 influenza virus in mammalian hosts. J Virol 2014; 88(6): 3568–3576

58. Xiao C, Ma W, Sun N, Huang L, Li Y, Zeng Z, Wen Y, Zhang Z, Li H, Li Q, Yu Y, Zheng Y, Liu S, Hu P, Zhang X, Ning Z, Qi W, Liao M. PB2-588 V promotes the mammalian adaptation of H10N8, H7N9 and H9N2 avian influenza viruses. Sci Rep 2016; 6(1): 19474

59. Liu WJ, Li J, Zou R, Pan J, Jin T, Li L, Liu P, Zhao Y, Yu X, Wang H, Liu G, Jiang H, Bi Y, Liu L, Yuen KY, Liu Y, Gao GF. Dynamic PB2-E627K substitution of influenza H7N9 virus indicates the *in vivo* genetic tuning and rapid host adaptation. Proc Natl Acad Sci U S A 2020; 117(38): 23807–23814

60. Bi Y, Xiao H, Chen Q, Wu Y, Fu L, Quan C, Wong G, Liu J, Haywood J, Liu Y, Zhou B, Yan J, Liu W, Gao GF. Changes in the length of the neuraminidase stalk region impact H7N9 virulence in mice. J Virol 2016; 90(4): 2142–2149

61. de Graaf M, Fouchier RA. Role of receptor binding specificity in influenza A virus transmission and pathogenesis. EMBO J 2014; 33(8): 823–841

62. Wiley DC, Skehel JJ. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem 1987; 56(1): 365–394

63. Shi Y, Wu Y, Zhang W, Qi J, Gao GF. Enabling the 'host jump': structural determinants of receptor-binding specificity in influenza A viruses. Nat Rev Microbiol 2014; 12(12): 822–831

64. Sun X, Shi Y, Lu X, He J, Gao F, Yan J, Qi J, Gao GF. Bat-derived influenza hemagglutinin H17 does not bind canonical avian or human receptors and most likely uses a unique entry mechanism. Cell Rep 2013; 3(3): 769–778

65. Wu Y, Wu Y, Tefsen B, Shi Y, Gao GF. Bat-derived influenza-like viruses H17N10 and H18N11. Trends Microbiol 2014; 22(4): 183–191

66. Taubenberger JK, Kash JC. Influenza virus evolution, host adaptation, and pandemic formation. Cell Host Microbe 2010; 7 (6): 440–451

67. Xiong XL, McCauley JW, Steinhauer DA. Receptor binding properties of the influenza virus hemagglutinin as a determinant of host range. Curr Top Microbiol Immunol 2014; 385: 63–91

68. Bao CJ, Cui LB, Zhou MH, Hong L, Gao GF, Wang H. Live-animal markets and influenza A (H7N9) virus infection. N Engl J Med 2013; 368(24): 2337–2339

69. Vijaykrishna D, Deng YM, Grau ML, Kay M, Suttie A, Horwood PF, Kalpravidh W, Claes F, Osbjer K, Dussart P, Barr IG, Karlsson EA. Emergence of influenza A (H7N4) virus, Cambodia. Emerg Infect Dis 2019; 25(10): 1988–1991

70. Xu Y, Peng R, Zhang W, Qi J, Song H, Liu S, Wang H, Wang M, Xiao H, Fu L, Fan Z, Bi Y, Yan J, Shi Y, Gao GF. Avian-to-human receptor-binding adaptation of avian H7N9 influenza virus hemagglutinin. Cell Rep 2019; 29(8): 2217–2228.e5

71. Shi Y, Zhang W, Wang F, Qi J, Wu Y, Song H, Gao F, Bi Y, Zhang Y, Fan Z, Qin C, Sun H, Liu J, Haywood J, Liu W, Gong W, Wang D, Shu Y, Wang Y, Yan J, Gao GF. Structures and receptor binding of hemagglutinins from human-infecting H7N9 influenza viruses. Science 2013; 342(6155): 243–247

72. Xiong X, Martin SR, Haire LF, Wharton SA, Daniels RS, Bennett MS, McCauley JW, Collins PJ, Walker PA, Skehel JJ, Gamblin SJ. Receptor binding by an H7N9 influenza virus from humans. Nature 2013; 499(7459): 496–499

73. Kageyama T, Fujisaki S, Takashita E, Xu H, Yamada S, Uchida Y, Neumann G, Saito T, Kawaoka Y, Tashiro M. Genetic analysis of novel avian A (H7N9) influenza viruses isolated from patients in China, February to April 2013. Euro Surveill 2013; 18(15): 20453

74. de Vries RP, Peng W, Grant OC, Thompson AJ, Zhu X, Bouwman KM, de la Pena ATT, van Breemen MJ, Ambepitiya Wickrama-singhe IN, de Haan CAM, Yu W, McBride R, Sanders RW, Woods RJ, Verheije MH, Wilson IA, Paulson JC. Three mutations switch H7N9 influenza to human-type receptor specificity. PLoS Pathog 2017; 13(6): e1006390

75. Wang Z, Zhang A, Wan Y, Liu X, Qiu C, Xi X, Ren Y, Wang J, Dong Y, Bao M, Li L, Zhou M, Yuan S, Sun J, Zhu Z, Chen L, Li Q, Zhang Z, Zhang X, Lu S, Doherty PC, Kedzierska K, Xu J. Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. Proc Natl Acad Sci USA 2014; 111(2): 769–774

76. Guo J, Huang F, Liu J, Chen Y, Wang W, Cao B, Zou Z, Liu S, Pan J, Bao C, Zeng M, Xiao H, Gao H, Yang S, Zhao Y, Liu Q, Zhou H, Zhu J, Liu X, Liang W, Yang Y, Zheng S, Yang J, Diao H, Su K, Shao L, Cao H, Wu Y, Zhao M, Tan S, Li H, Xu X, Wang C, Zhang J, Wang L, Wang J, Xu J, Li D, Zhong N, Cao X, Gao GF, Li L, Jiang C. The serum profile of hypercytokinemia factors identified in H7N9-Infected patients can predict fatal outcomes. Sci Rep 2015; 5(1): 10942

77. Huang F, Guo J, Zou Z, Liu J, Cao B, Zhang S, Li H, Wang W, Sheng M, Liu S, Pan J, Bao C, Zeng M, Xiao H, Qian G, Hu X, Chen Y, Chen Y, Zhao Y, Liu Q, Zhou H, Zhu J, Gao H, Yang S, Liu X, Zheng S, Yang J, Diao H, Cao H, Wu Y, Zhao M, Tan S, Guo D, Zhao X, Ye Y, Wu W, Xu Y, Penninger JM, Li D, Gao GF, Jiang C, Li L. Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients. Nat Commun 2014; 5(1): 3595

78. Chen Y, Liang W, Yang S, Wu N, Gao H, Sheng J, Yao H, Wo J, Fang Q, Cui D, Li Y, Yao X, Zhang Y, Wu H, Zheng S, Diao H, Xia S, Zhang Y, Chan KH, Tsoi HW, Teng JL, Song W, Wang P, Lau SY, Zheng M, Chan JF, To KK, Chen H, Li L, Yuen KY. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Lancet 2013; 381(9881): 1916–1925

79. Bi Y, Liu J, Xiong H, Zhang Y, Liu D, Liu Y, Gao GF, Wang B. A new reassortment of influenza A (H7N9) virus causing human infection in Beijing, 2014. Sci Rep 2016; 6(1): 26624

80. Chi Y, Zhu Y, Wen T, Cui L, Ge Y, Jiao Y, Wu T, Ge A, Ji H, Xu K, Bao C, Zhu Z, Qi X, Wu B, Shi Z, Tang F, Xing Z, Zhou M. Cytokine and chemokine levels in patients infected with the novel avian influenza A (H7N9) virus in China. J Infect Dis 2013; 208 (12): 1962–1967

81. Zhou J, Wang D, Gao R, Zhao B, Song J, Qi X, Zhang Y, Shi Y,

Yang L, Zhu W, Bai T, Qin K, Lan Y, Zou S, Guo J, Dong J, Dong L, Zhang Y, Wei H, Li X, Lu J, Liu L, Zhao X, Li X, Huang W, Wen L, Bo H, Xin L, Chen Y, Xu C, Pei Y, Yang Y, Zhang X, Wang S, Feng Z, Han J, Yang W, Gao GF, Wu G, Li D, Wang Y, Shu Y. Biological features of novel avian influenza A (H7N9) virus. Nature 2013; 499(7459): 500–503

82. Bi Y, Tan S, Yang Y, Wong G, Zhao M, Zhang Q, Wang Q, Zhao X, Li L, Yuan J, Li H, Li H, Xu W, Shi W, Quan C, Zou R, Li J, Zheng H, Yang L, Liu WJ, Liu D, Wang H, Qin Y, Liu L, Jiang C, Liu W, Lu L, Gao GF, Liu Y. Clinical and immunological characteristics of human infections with H5N6 avian influenza virus. Clin Infect Dis 2019; 68(7): 1100–1109

83. Chen Y, Li X, Tian L, Zheng S, Yang S, Dong Y, Wang Y, Cui D, Liu X, Liang W, Chen H, Li L. Dynamic behavior of lymphocyte subgroups correlates with clinical outcomes in human H7N9 infection. J Infect 2014; 69(4): 358–365

84. Diao H, Cui G, Wei Y, Chen J, Zuo J, Cao H, Chen Y, Yao H, Tian Z, Li L. Severe H7N9 infection is associated with decreased antigen-presenting capacity of CD14+ cells. PLoS One 2014; 9(3): e92823

85. Wang Z, Wan Y, Qiu C, Quiñones-Parra S, Zhu Z, Loh L, Tian D, Ren Y, Hu Y, Zhang X, Thomas PG, Inouye M, Doherty PC, Kedzierska K, Xu J. Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8+ T cells. Nat Commun 2015; 6(1): 6833

86. Wang Z, Zhu L, Nguyen THO, Wan Y, Sant S, Quiñones-Parra SM, Crawford JC, Eltahla AA, Rizzetto S, Bull RA, Qiu C, Koutsakos M, Clemens EB, Loh L, Chen T, Liu L, Cao P, Ren Y, Kedzierski L, Kotsimbos T, McCaw JM, La Gruta NL, Turner SJ, Cheng AC, Luciani F, Zhang X, Doherty PC, Thomas PG, Xu J, Kedzierska K. Clonally diverse CD38+HLA-DR+CD8+ T cells persist during fatal H7N9 disease. Nat Commun 2018; 9(1): 824

87. Hou D, Ying T, Wang L, Chen C, Lu S, Wang Q, Seeley E, Xu J, Xi X, Li T, Liu J, Tang X, Zhang Z, Zhou J, Bai C, Wang C, Byrne-Steele M, Qu J, Han J, Song Y. Immune repertoire diversity correlated with mortality in avian influenza A (H7N9) virus infected patients. Sci Rep 2016; 6(1): 33843

88. Chen J, Cui G, Lu C, Ding Y, Gao H, Zhu Y, Wei Y, Wang L, Uede T, Li L, Diao H. Severe infection with avian influenza A virus is associated with delayed immune recovery in survivors. Medicine (Baltimore) 2016; 95(5): e2606

89. Zhao M, Chen J, Tan S, Dong T, Jiang H, Zheng J, Quan C, Liao Q, Zhang H, Wang X, Wang Q, Bi Y, Liu F, Feng L, Horby PW, Klenerman P, Gao GF, Liu WJ, Yu H. Prolonged evolution of virus-specific memory T cell immunity after severe avian influenza A (H7N9) virus infection. J Virol 2018; 92(17): e01024-18

90. Ma MJ, Wang XX, Wu MN, Wang XJ, Bao CJ, Zhang HJ, Yang Y, Xu K, Wang GL, Zhao M, Cheng W, Chen WJ, Zhang WH, Fang LQ, Liu WJ, Chen EF, Cao WC. Characterization of antibody and memory T-cell response in H7N9 survivors: a cross-sectional analysis. Clin Microbiol Infect 2020; 26(2): 247–254

91. van de Sandt CE, Kreijtz JH, de Mutsert G, Geelhoed-Mieras MM, Hillaire ML, Vogelzang-van Trierum SE, Osterhaus AD, Fouchier RA, Rimmelzwaan GF. Human cytotoxic T lymphocytes directed to seasonal influenza A viruses cross-react with the newly emerging H7N9 virus. J Virol 2014; 88(3): 1684–1693

92. Liu WJ, Tan S, Zhao M, Quan C, Bi Y, Wu Y, Zhang S, Zhang H,

Xiao H, Qi J, Yan J, Liu W, Yu H, Shu Y, Wu G, Gao GF. Cross-immunity against avian influenza A (H7N9) virus in the healthy population is affected by antigenicity-dependent substitutions. J Infect Dis 2016; 214(12): 1937–1946

93. Quiñones-Parra S, Grant E, Loh L, Nguyen TH, Campbell KA, Tong SY, Miller A, Doherty PC, Vijaykrishna D, Rossjohn J, Gras S, Kedzierska K. Preexisting CD8+ T-cell immunity to the H7N9 influenza A virus varies across ethnicities. Proc Natl Acad Sci USA 2014; 111(3): 1049–1054

94. Liu J, Wu B, Zhang S, Tan S, Sun Y, Chen Z, Qin Y, Sun M, Shi G, Wu Y, Sun M, Liu N, Ning K, Ma Y, Gao B, Yan J, Zhu F, Wang H, Gao GF. Conserved epitopes dominate cross-CD8+ T-cell responses against influenza A H1N1 virus among Asian populations. Eur J Immunol 2013; 43(8): 2055–2069

95. Zhao M, Liu K, Luo J, Tan S, Quan C, Zhang S, Chai Y, Qi J, Li Y, Bi Y, Xiao H, Wong G, Zhou J, Jiang T, Liu W, Yu H, Yan J, Liu Y, Shu Y, Wu G, Wu A, Gao GF, Liu WJ. Heterosubtypic protections against human-infecting avian influenza viruses correlate to biased cross-T-cell responses. MBio 2018; 9(4): e01408-18

96. Duan S, Meliopoulos VA, McClaren JL, Guo XZ, Sanders CJ, Smallwood HS, Webby RJ, Schultz-Cherry SL, Doherty PC, Thomas PG. Diverse heterologous primary infections radically alter immunodominance hierarchies and clinical outcomes following H7N9 influenza challenge in mice. PLoS Pathog 2015; 11(2): e1004642

97. McMaster SR, Gabbard JD, Koutsonanos DG, Compans RW, Tripp RA, Tompkins SM, Kohlmeier JE. Memory T cells generated by prior exposure to influenza cross react with the novel H7N9 influenza virus and confer protective heterosubtypic immunity. PLoS One 2015; 10(2): e0115725

98. Chen Z, Wang J, Bao L, Guo L, Zhang W, Xue Y, Zhou H, Xiao Y, Wang J, Wu F, Deng Y, Qin C, Jin Q. Human monoclonal antibodies targeting the haemagglutinin glycoprotein can neutralize H7N9 influenza virus. Nat Commun 2015; 6(1): 6714

99. Wang J, Chen Z, Bao L, Zhang W, Xue Y, Pang X, Zhang X, Qin C, Jin Q. Characterization of two human monoclonal antibodies neutralizing influenza A H7N9 viruses. J Virol 2015; 89(17): 9115–9118

100. Huang KA, Rijal P, Jiang H, Wang B, Schimanski L, Dong T, Liu YM, Chang P, Iqbal M, Wang MC, Chen Z, Song R, Huang CC, Yang JH, Qi J, Lin TY, Li A, Powell TJ, Jan JT, Ma C, Gao GF, Shi Y, Townsend AR. Structure-function analysis of neutralizing antibodies to H7N9 influenza from naturally infected humans. Nat Microbiol 2019; 4(2): 306–315

101. Li M, Chen L, Wang Q, Hao M, Zhang X, Liu L, Yu X, Yang C, Xu J, Chen J, Gong R. A cross-reactive human monoclonal antibody targets the conserved H7 antigenic site A from fifth wave H7N9-infected humans. Antiviral Res 2019; 170: 104556

102. Li J, Yang Y, Wang M, Ren X, Yang Z, Liu L, Zhang G, Chen Q, Yang W, Chen YH, Wan X. Rapid isolation of a potent human antibody against H7N9 influenza virus from an infected patient. Antiviral Res 2019; 170: 104564

103. Henry Dunand CJ, Leon PE, Huang M, Choi A, Chromikova V, Ho IY, Tan GS, Cruz J, Hirsh A, Zheng NY, Mullarkey CE, Ennis FA, Terajima M, Treanor JJ, Topham DJ, Subbarao K, Palese P, Krammer F, Wilson PC. Both neutralizing and non-neutralizing

human H7N9 influenza vaccine-induced monoclonal antibodies confer protection. Cell Host Microbe 2016; 19(6): 800–813

104. Thornburg NJ, Zhang H, Bangaru S, Sapparapu G, Kose N, Lampley RM, Bombardi RG, Yu Y, Graham S, Branchizio A, Yoder SM, Rock MT, Creech CB, Edwards KM, Lee D, Li S, Wilson IA, García-Sastre A, Albrecht RA, Crowe JE Jr. H7N9 influenza virus neutralizing antibodies that possess few somatic mutations. J Clin Invest 2016; 126(4): 1482–1494

105. Tan GS, Leon PE, Albrecht RA, Margine I, Hirsh A, Bahl J, Krammer F. Broadly-reactive neutralizing and non-neutralizing antibodies directed against the H7 influenza virus hemagglutinin reveal divergent mechanisms of protection. PLoS Pathog 2016; 12 (4): e1005578

106. Schmeisser F, Vasudevan A, Verma S, Wang W, Alvarado E, Weiss C, Atukorale V, Meseda C, Weir JP. Antibodies to antigenic site A of influenza H7 hemagglutinin provide protection against H7N9 challenge. PLoS One 2015; 10(1): e0117108

107. Stadlbauer D, Amanat F, Strohmeier S, Nachbagauer R, Krammer F. Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A/Shanghai/1/2013 (H7N9) protect against novel H7 virus isolates in the mouse model. Emerg Microbes Infect 2018; 7(1): 110

108. He F, Kumar SR, Syed Khader SM, Tan Y, Prabakaran M, Kwang J. Effective intranasal therapeutics and prophylactics with mono-clonal antibody against lethal infection of H7N7 influenza virus. Antiviral Res 2013; 100(1): 207–214

109. Chen C, Liu L, Xiao Y, Cui S, Wang J, Jin Q. Structural insight into a human neutralizing antibody against influenza virus H7N9. J Virol 2018; 92(5): e01850-17

110. Yu F, Song H, Wu Y, Chang SY, Wang L, Li W, Hong B, Xia S, Wang C, Khurana S, Feng Y, Wang Y, Sun Z, He B, Hou D, Manischewitz J, King LR, Song Y, Min JY, Golding H, Ji X, Lu L, Jiang S, Dimitrov DS, Ying T. A potent germline-like human monoclonal antibody targets a pH-sensitive epitope on H7N9 influenza hemagglutinin. Cell Host Microbe 2017; 22(4): 471–483. e5

111. Hong M, Lee PS, Hoffman RM, Zhu X, Krause JC, Laursen NS, Yoon SI, Song L, Tussey L, Crowe JE Jr, Ward AB, Wilson IA. Antibody recognition of the pandemic H1N1 Influenza virus hemagglutinin receptor binding site. J Virol 2013; 87(22): 12471–12480

112. Whittle JRR, Zhang R, Khurana S, King LR, Manischewitz J, Golding H, Dormitzer PR, Haynes BF, Walter EB, Moody MA, Kepler TB, Liao HX, Harrison SC. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci USA 2011; 108(34): 14216–14221

113. Xu R, Krause JC, McBride R, Paulson JC, Crowe JE Jr, Wilson IA. A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin. Nat Struct Mol Biol 2013; 20(3): 363–370

114. Laursen NS, Wilson IA. Broadly neutralizing antibodies against influenza viruses. Antiviral Res 2013; 98(3): 476–483

115. Ekiert DC, Kashyap AK, Steel J, Rubrum A, Bhabha G, Khayat R, Lee JH, Dillon MA, O'Neil RE, Faynboym AM, Horowitz M, Horowitz L, Ward AB, Palese P, Webby R, Lerner RA, Bhatt RR, Wilson IA. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 2012; 489(7417): 526–532

116. Lee PS, Ohshima N, Stanfield RL, Yu W, Iba Y, Okuno Y, Kurosawa Y, Wilson IA. Receptor mimicry by antibody F045-092 facilitates universal binding to the H3 subtype of influenza virus. Nat Commun 2014; 5(1): 3614

117. Lee PS, Yoshida R, Ekiert DC, Sakai N, Suzuki Y, Takada A, Wilson IA. Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Proc Natl Acad Sci USA 2012; 109(42): 17040–17045

118. Yoshida R, Igarashi M, Ozaki H, Kishida N, Tomabechi D, Kida H, Ito K, Takada A. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog 2009; 5(3): e1000350

119. Bangaru S, Lang S, Schotsaert M, Vanderven HA, Zhu X, Kose N, Bombardi R, Finn JA, Kent SJ, Gilchuk P, Gilchuk I, Turner HL, Garcia-Sastre A, Li S, Ward AB, Wilson IA, Crowe JE, Jr. A site of vulnerability on the influenza virus hemagglutinin head domain trimer interface. Cell 2019; 177(5): 1136–1152.e18

120. Okuno Y, Isegawa Y, Sasao F, Ueda S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 1993; 67(5): 2552–2558

121. Sedeyn K, Saelens X. New antibody-based prevention and treatment options for influenza. Antiviral Res 2019; 170: 104562

122. Xiao H, Guo T, Yang M, Qi J, Huang C, Hong Y, Gu J, Pang X, Liu WJ, Peng R, McCauley J, Bi Y, Li S, Feng J, Zhang H, Zhang X, Lu X, Yan J, Chen L, Shi Y, Chen W, Gao GF. Light chain modulates heavy chain conformation to change protection profile of monoclonal antibodies against influenza A viruses. Cell Discov 2019; 5(1): 21

123. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, Lee JH, Metlagel Z, Bujny MV, Jongeneelen M, van der Vlugt R, Lamrani M, Korse HJ, Geelen E, Sahin Ö, Sieuwerts M, Brakenhoff JP, Vogels R, Li OT, Poon LL, Peiris M, Koudstaal W, Ward AB, Wilson IA, Goudsmit J, Friesen RH. Highly conserved protective epitopes on influenza B viruses. Science 2012; 337 (6100): 1343–1348

124. Eichelberger MC, Wan H. Influenza neuraminidase as a vaccine antigen. Curr Top Microbiol Immunol 2015; 386: 275–299

125. Wilson JR, Guo Z, Reber A, Kamal RP, Music N, Gansebom S, Bai Y, Levine M, Carney P, Tzeng WP, Stevens J, York IA. An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity *in vivo*. Antiviral Res 2016; 135: 48–55

126. Li J, Yu X, Pu X, Xie L, Sun Y, Xiao H, Wang F, Din H, Wu Y, Liu D, Zhao G, Liu J, Pan J. Environmental connections of novel avian-origin H7N9 influenza virus infection and virus adaptation to the human. Sci China Life Sci 2013; 56(6): 485–492

127. Wan H, Qi L, Gao J, Couzens LK, Jiang L, Gao Y, Sheng ZM, Fong S, Hahn M, Khurana S, Taubenberger JK, Eichelberger MC. Comparison of the efficacy of N9 neuraminidase-specific mono-clonal antibodies against influenza A (H7N9) virus infection. J Virol 2018; 92(4): e01588-17

128. Gilchuk IM, Bangaru S, Gilchuk P, Irving RP, Kose N, Bombardi RG, Thornburg NJ, Creech CB, Edwards KM, Li S, Turner HL, Yu W, Zhu X, Wilson IA, Ward AB, Crowe JE, Jr. Influenza H7N9 virus neuraminidase-specific human monoclonal antibodies inhibit viral egress and protect from lethal influenza infection in mice. Cell Host Microbe 2019; 26(6): 715–728.e8

129. Rijal P, Wang BB, Tan TK, Schimanski L, Janesch P, Dong T,

McCauley JW, Daniels RS, Townsend AR, Huang KA. Broadly inhibiting anti-neuraminidase monoclonal antibodies induced by trivalent influenza vaccine and H7N9 infection in humans. J Virol 2020; 94(4): e01182-19

130. Jiang H, Peng W, Qi J, Chai Y, Song H, Bi Y, Rijal P, Wang H, Oladejo BO, Liu J, Shi Y, Gao GF, Townsend AR, Wu Y. Structure-based modification of an anti-neuraminidase human antibody restores protection efficacy against the drifted influenza virus. mBio 2020; 11(5):e02315-20

131. Chen YQ, Wohlbold TJ, Zheng NY, Huang M, Huang Y, Neu KE, Lee J, Wan H, Rojas KT, Kirkpatrick E, Henry C, Palm AE, Stamper CT, Lan LY, Topham DJ, Treanor J, Wrammert J, Ahmed R, Eichelberger MC, Georgiou G, Krammer F, Wilson PC. Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies. Cell 2018; 173(2): 417–429.e10

132. Tang J, Wang D. Research progress in human infection with avian influenza H7N9 virus. Sci China Life Sci 2017; 60(12): 1299–1306

133. Isakova-Sivak I, Rudenko L. Tackling a novel lethal virus: a focus on H7N9 vaccine development. Expert Rev Vaccines 2017; 16(7): 709–721

134. Wodal W, Schwendinger MG, Savidis-Dacho H, Crowe BA, Hohenadl C, Fritz R, Brhl P, Portsmouth D, Karner-Pichl A, Balta D, Grillberger L, Kistner O, Barrett PN, Howard MK. Immunogenicity and protective efficacy of a Vero cell culture-derived whole-virus H7N9 vaccine in mice and guinea pigs. PLoS One 2015; 10(2): e0113963

135. Chu DH, Sakoda Y, Nishi T, Hiono T, Shichinohe S, Okamatsu M, Kida H. Potency of an inactivated influenza vaccine prepared from A/duck/Mongolia/119/2008 (H7N9) against the challenge with A/Anhui/1/2013 (H7N9). Vaccine 2014; 32(28): 3473–3479

136. No authors listed. Zoonotic influenza viruses: antigenic and genetic characteristics and development of candidate vaccine viruses for pandemic preparedness. Wkly Epidemiol Rec 2016; 91(42): 485–499 (in French)

137. Seo SH, Kim HS. Inactivated antigen of the H7N9 influenza virus protects mice from its lethal infection. Viral Immunol 2016; 29(4): 235–243

138. Pan W, Han L, Dong Z, Niu X, Li Z, Bao L, Li C, Luo Q, Yang Z, Li X, Huang J, Feng L, Qin C, Zhong N, Chen L. Induction of neutralizing antibodies to influenza A virus H7N9 by inactivated whole virus in mice and nonhuman primates. Antiviral Res 2014; 107: 1–5

139. Chia MY, Hu AY, Tseng YF, Weng TC, Lai CC, Lin JY, Chen PL, Wang YF, Chao SR, Chang JY, Hwang YS, Yeh CT, Yu CP, Chen YC, Su IJ, Lee MS. Evaluation of MDCK cell-derived influenza H7N9 vaccine candidates in ferrets. PLoS One 2015; 10(3): e0120793

140. Barría MI, Garrido JL, Stein C, Scher E, Ge Y, Engel SM, Kraus TA, Banach D, Moran TM. Localized mucosal response to intranasal live attenuated influenza vaccine in adults. J Infect Dis 2013; 207(1): 115–124

141. Petukhova G, Naikhin A, Chirkova T, Donina S, Korenkov D, Rudenko L. Comparative studies of local antibody and cellular immune responses to influenza infection and vaccination with live attenuated reassortant influenza vaccine (LAIV) utilizing a mouse nasal-associated lymphoid tissue (NALT) separation method. Vaccine 2009; 27(19): 2580–2587

142. Powell TJ, Strutt T, Reome J, Hollenbaugh JA, Roberts AD, Woodland DL, Swain SL, Dutton RW. Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus. J Immunol 2007; 178(2): 1030–1038

143. Tamura S, Tanimoto T, Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis 2005; 58(4): 195–207

144. Chirkova TV, Naykhin AN, Petukhova GD, Korenkov DA, Donina SA, Mironov AN, Rudenko LG. Memory T-cell immune response in healthy young adults vaccinated with live attenuated influenza A (H5N2) vaccine. Clin Vaccine Immunol 2011; 18(10): 1710–1718

145. He XS, Holmes TH, Zhang C, Mahmood K, Kemble GW, Lewis DB, Dekker CL, Greenberg HB, Arvin AM. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 2006; 80(23): 11756–11766

146. Hoft DF, Babusis E, Worku S, Spencer CT, Lottenbach K, Truscott SM, Abate G, Sakala IG, Edwards KM, Creech CB, Gerber MA, Bernstein DI, Newman F, Graham I, Anderson EL, Belshe RB. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 2011; 204(6): 845–853

147. Isakova-Sivak I, Rudenko L. Safety, immunogenicity and infectivity of new live attenuated influenza vaccines. Expert Rev Vaccines 2015; 14(10): 1313–1329

148. Chen Z, Baz M, Lu J, Paskel M, Santos C, Subbarao K, Jin H, Matsuoka Y. Development of a high-yield live attenuated H7N9 influenza virus vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets. J Virol 2014; 88(12): 7016–7023

149. Yang X, Zhao J, Wang C, Duan Y, Zhao Z, Chen R, Zhang L, Xing L, Lai C, Zhang S, Wang X, Yang P. Immunization with a live attenuated H7N9 influenza vaccine protects mice against lethal challenge. PLoS One 2015; 10(4): e0123659

150. Kong H, Zhang Q, Gu C, Shi J, Deng G, Ma S, Liu J, Chen P, Guan Y, Jiang Y, Chen H. A live attenuated vaccine prevents replication and transmission of H7N9 virus in mammals. Sci Rep 2015; 5(1): 11233

151. Shcherbik S, Pearce N, Balish A, Jones J, Thor S, Davis CT, Pearce M, Tumpey T, Cureton D, Chen LM, Villanueva J, Bousse TL. Generation and characterization of live attenuated influenza A (H7N9) candidate vaccine virus based on Russian donor of attenuation. PLoS One 2015; 10(9): e0138951

152. Fries LF, Smith GE, Glenn GM. A recombinant viruslike particle influenza A (H7N9) vaccine. N Engl J Med 2013; 369(26): 2564–2566

153. Liu YV, Massare MJ, Pearce MB, Sun X, Belser JA, Maines TR, Creager HM, Glenn GM, Pushko P, Smith GE, Tumpey TM. Recombinant virus-like particles elicit protective immunity against avian influenza A (H7N9) virus infection in ferrets. Vaccine 2015; 33(18): 2152–2158

154. Pillet S, Racine T, Nfon C, Di Lenardo TZ, Babiuk S, Ward BJ, Kobinger GP, Landry N. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets. Vaccine 2015; 33(46): 6282–6289

155. Feng L, Feng S, Chen T, Yang J, Lau YC, Peng Z, Li L, Wang X, Wong JYT, Qin Y, Bond HS, Zhang J, Fang VJ, Zheng J, Yang J,

Wu P, Jiang H, He Y, Cowling BJ, Yu H, Shu Y, Lau EHY. Burden of influenza-associated outpatient influenza-like illness consultations in China, 2006–2015: a population-based study. Influenza Other Respir Viruses 2020; 14(2): 162–172

156. Rasmussen SA, Redd SC. Using results from infectious disease modeling to improve the response to a potential H7N9 influenza pandemic. Clin Infect Dis 2015; 60(Suppl 1): S9–S10

157. Qi X, Jiang D, Wang H, Zhuang D, Ma J, Fu J, Qu J, Sun Y, Yu S, Meng Y, Huang Y, Xia L, Li Y, Wang Y, Wang G, Xu K, Zhang Q, Wan M, Su X, Fu G, Gao GF. Calculating the burden of disease of avian-origin H7N9 infections in China. BMJ Open 2014; 4(1): e004189

158. Huo X, Chen LL, Hong L, Xiang LH, Tang FY, Chen SH, Gao Q, Chen C, Dai QG, Sun CW, Xu K, Dai WJ, Qi X, Li CC, Yu HY, Zhou Y, Huang HD, Pan XY, Xu CS, Zhou MH, Bao CJ. Economic burden and its associated factors of hospitalized patients infected with A (H7N9) virus: a retrospective study in Eastern China, 2013–2014. Infect Dis Poverty 2016; 5(1): 79

159. Sutton TC. The pandemic threat of emerging H5 and H7 avian influenza viruses. Viruses 2018; 10(9): E461

160. Jernigan DB, Cox NJ. H7N9: preparing for the unexpected in influenza. Annu Rev Med 2015; 66(1): 361–371

161. Silva W, Das TK, Izurieta R. Estimating disease burden of a potential A (H7N9) pandemic influenza outbreak in the United States. BMC Public Health 2017; 17(1): 898

162. WHO. Human infection with avian influenza (H7N9) virus—China: update. 2018. https://www.who.int/csr/don/05-september-2018-ah7n9-china/en/ (accessed October 20, 2020)

163. Su K, Ye S, Li Q, Xie W, Yu H, Qi L, Xiong Y, Zhao H, Li B, Ling H, Tang Y, Xiao B, Rong R, Tang W, Li Y. Influenza A (H7N9) virus emerged and resulted in human infections in Chongqing, southwestern China since 2017. Int J Infect Dis 2019; 81: 244–250

164. Yu D, Xiang G, Zhu W, Lei X, Li B, Meng Y, Yang L, Jiao H, Li X, Huang W, Wei H, Zhang Y, Hai Y, Zhang H, Yue H, Zou S, Zhao X, Li C, Ao D, Zhang Y, Tan M, Liu J, Zhang X, Gao GF, Meng L, Wang D. The re-emergence of highly pathogenic avian influenza H7N9 viruses in humans in mainland of China, 2019. Euro Surveill 2019; 24(21): 1900273

165. Shi W, Ke C, Fang S, Li J, Song H, Li X, Hu T, Wu J, Chen T, Yi L, Song Y, Wang X, Xing W, Huang W, Xiao H, Liang L, Peng B, Wu W, Liu H, Liu WJ, Holmes EC, Gao GF, Wang D. Co-circulation and persistence of multiple A/H3N2 influenza variants in China. Emerg Microbes Infect 2019; 8(1): 1157–1167

166. Wang P, Liu WJ. It's not just science: challenges for public health intervention in Ebola epidemics in the Democratic Republic of Congo. Sci China Life Sci 2020; 63(7): 1079–1081

167. Quan C, Wang Q, Zhang J, Zhao M, Dai Q, Huang T, Zhang Z, Mao S, Nie Y, Liu J, Xie Y, Zhang B, Bi Y, Shi W, Liu P, Wang D, Feng L, Yu H, Liu WJ, Gao GF. Avian influenza A viruses among occupationally exposed populations, China, 2014–2016. Emerg Infect Dis 2019; 25(12): 2215–2225

168. OIE. Update on avian influenza in animals (types H5 and H7). https://www.oie.int/en/animal-health-in-the-world/update-on-avian-influenza/2018/ (accessed March 29, 2021)

169. Bulach D, Halpin R, Spiro D, Pomeroy L, Janies D, Boyle DB. Molecular analysis of H7 avian influenza viruses from Australia and New Zealand: genetic diversity and relationships from 1976 to 2007. J Virol 2010; 84(19): 9957–9966

170. Huo X, Cui LB, Chen C, Wang D, Qi X, Zhou MH, Guo X, Wang F, Liu WJ, Kong W, Ni D, Chi Y, Ge Y, Huang H, Hu F, Li C, Zhao X, Ren R, Bao CJ, Gao GF, Zhu FC. Severe human infection with a novel avian-origin influenza A (H7N4) virus. Sci Bull (Beijing) 2018; 63(16): 1043–1050

171. Quan C, Huang T, Chen X, Zhang J, Wang Q, Zhang C, Zhang T, Zhou L, Shu L, Long C, Yang L, Du X, Zhao Y, Liu P, Song H, Shi W, Bi Y, Lv Q, Liu WJ, Gao GF. Genomic characterizations of H4 subtype avian influenza viruses from live poultry markets in Sichuan Province of China, 2014–2015. Sci China Life Sci 2018; 61(9): 1123–1126

172. Gao GF. Foreword: Foreword from Editor-in-Chief George F. Gao — China's outreach to the world: public health goes global. China CDC Week 2019; 1(1): 1–2

173. Wu G. Laboratory biosafety in China: past, present, and future. Biosafety Heal 2019; 1(2): 56–58

174. Liu Q, Zhou B, Ma W, Bawa B, Ma J, Wang W, Lang Y, Lyoo Y, Halpin RA, Lin X, Stockwell TB, Webby R, Wentworth DE, Richt JA. Analysis of recombinant H7N9 wild-type and mutant viruses in pigs shows that the Q226L mutation in HA is important for transmission. J Virol 2014; 88(14): 8153–8165

175. Mok CK, Lee HH, Chan MC, Sia SF, Lestra M, Nicholls JM, Zhu H, Guan Y, Peiris JM. Pathogenicity of the novel A/H7N9 influenza virus in mice. MBio 2013; 4(4): e00362-13

176. Sun X, Belser JA, Yang H, Pulit-Penaloza JA, Pappas C, Brock N, Zeng H, Creager HM, Stevens J, Maines TR. Identification of key hemagglutinin residues responsible for cleavage, acid stability, and virulence of fifth-wave highly pathogenic avian influenza A (H7N9) viruses. Virology 2019; 535: 232–240

177. Li W, Lee HHY, Li RF, Zhu HM, Yi G, Peiris JSM, Yang ZF, Mok CKP. The PB2 mutation with lysine at 627 enhances the pathogenicity of avian influenza (H7N9) virus which belongs to a non-zoonotic lineage. Sci Rep 2017; 7(1): 2352

178. Liang L, Jiang L, Li J, Zhao Q, Wang J, He X, Huang S, Wang Q, Zhao Y, Wang G, Sun N, Deng G, Shi J, Tian G, Zeng X, Jiang Y, Liu L, Liu J, Chen P, Bu Z, Kawaoka Y, Chen H, Li C. Low polymerase activity attributed to PA drives the acquisition of the PB2 E627K mutation of H7N9 avian influenza virus in mammals. MBio 2019; 10(3): e01162-19

179. Chan LL, Bui CT, Mok CK, Ng MM, Nicholls JM, Peiris JS, Chan MC, Chan RW. Evaluation of the human adaptation of influenza A/H7N9 virus in PB2 protein using human and swine respiratory tract explant cultures. Sci Rep 2016; 6(1): 35401

180. Zhu W, Zou X, Zhou J, Tang J, Shu Y. Residues 41V and/or 210D in the NP protein enhance polymerase activities and potential replication of novel influenza (H7N9) viruses at low temperature. Virol J 2015; 12(1): 71

181. Ma S, Zhang B, Shi J, Yin X, Wang G, Cui P, Liu L, Deng G, Jiang Y, Li C, Chen H. Amino acid mutations A286V and T437M in the nucleoprotein attenuate H7N9 viruses in mice. J Virol 2019; 94(2): e01530-19

182. Wang S, Zhang L, Zhang R, Chi X, Yang Z, Xie Y, Shu S, Liao Y, Chen JL. Identification of two residues within the NS1 of H7N9 influenza A virus that critically affect the protein stability and function. Vet Res (Faisalabad) 2018; 49(1): 98